1
|
Smith RP, Lawes J, Davies RH, Hutchison ML, Vidal A, Gilson D, Rodgers J. UK-wide risk factor study of broiler carcases highly contaminated with Campylobacter. Zoonoses Public Health 2023; 70:523-541. [PMID: 37337320 DOI: 10.1111/zph.13063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 04/04/2023] [Accepted: 05/22/2023] [Indexed: 06/21/2023]
Abstract
Campylobacter is a major cause of food poisoning and is typically the most common cause of gastroenteritis in the UK. Data collected at broiler farm and abattoir level, for slaughter batches that were sampled for UK-wide monitoring, were used to generate two epidemiological risk factor models. A total of 483 batches slaughtered between January 2016 and March 2017 were used in the analysis, coming from 19 abattoirs representing more than 85% of UK broiler production. For each selected slaughter batch, one carcase was sampled after primary chilling and 10 randomly sampled birds had caecal samples collected at the evisceration point. Samples were used for Campylobacter identification and quantification. Two multivariable mixed-effects models were designed, one with the binary outcome for the detection of a highly contaminated (>1000 colony forming units (CFU)/g) Campylobacter-positive carcase, whereas the other used the Campylobacter colony count (CFU/g) carcase outcome. The results suggest that caecal colonization within the batch was a key factor for the occurrence of Campylobacter on carcases, and many factors that were identified in the model were also likely to be related to colonization or related to the risk of introduction of Campylobacter from partial depopulation (referred to as thinning) of ~30% of the flock approximately 1 week before full flock depopulation events. The amount of neck skin in the sample was another key factor identified and was included in both models as a risk factor. The models have also identified other factors which may be related to the general health and husbandry on-farm (use of prebiotics or vaccines, and identification of the product used for drinking line cleaning), whereas the other factors may identify control points related to transmission within a farm. The identification of these variables could help focus control efforts on-farm, especially for relatively easy improvements, such as improving the provision of house-specific bird-weighing buckets/cages in houses.
Collapse
Affiliation(s)
- R P Smith
- Department of Epidemiological Sciences, Animal and Plant Health Agency - Weybridge, Surrey, UK
| | - J Lawes
- Department of Epidemiological Sciences, Animal and Plant Health Agency - Weybridge, Surrey, UK
| | - R H Davies
- Bacteriology Department, Animal and Plant Health Agency - Weybridge, Surrey, UK
| | | | - A Vidal
- Bacteriology Department, Animal and Plant Health Agency - Weybridge, Surrey, UK
- Surveillance and Regulatory Support Department, European Medicines Agency, Amsterdam, The Netherlands
| | - D Gilson
- Department of Epidemiological Sciences, Animal and Plant Health Agency - Weybridge, Surrey, UK
- Faculty of Biological Sciences, University of Leeds, West Yorkshire, UK
| | - J Rodgers
- Bacteriology Department, Animal and Plant Health Agency - Weybridge, Surrey, UK
| |
Collapse
|
2
|
Kipp B, Vidal A, Lenick D, Christmann-Schmid C. Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland. J Ovarian Res 2023; 16:20. [PMID: 36691070 PMCID: PMC9869527 DOI: 10.1186/s13048-023-01107-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 01/19/2023] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Borderline tumors are malignant epithelial ovarian tumors with a very low incidence. Thus experience in diagnostics and treatment is still rare. The aim of this study was to present and analyze data of women with borderline ovarian tumor (BOT) regarding clinical features, histological characteristics, diagnostics and treatment management. METHODS In this single center retrospective study women with BOT treated at the Departement of Gynecology and Obstetrics at the Kantonsspital Luzern between 2011 and 2018 were analyzed according to their clinical and histological reports. RESULTS A total of 42 women were enrolled. The median age was 58.5 with a range from 26 to 85, of which 31 (73.8%) were postmenopausal. Regarding the histological subtypes, 23 women (54.8%) had serous and 15 (35.7%) had mucinous BOT. Seromucinous histology was found in 3 patients (7.1%) and endometrioid in 1 woman (2.4%), respectively. All women underwent surgery. In a total of 39 women (92.9%) a complete surgical staging for BOT was performed. In 29 women (69.0%) staging was performed by laparoscopy, 13 (31.0%) underwent laparotomy. The mean follow up was 52 months (range = 16.3-101.4 months). During this period two patients, initially diagnosed in FIGO stage 1, recurred after 21.7 and 44 months, respectively, the second woman died after 53 months because of the BOT. CONCLUSION In the present study women were treated according to the international therapy recommendations and the rate of recurrence was very low. The most common risk factors for relapse are known to be FIGO stage, incomplete staging and peritoneal implants but were not present in our group. Thus further studies are necessary to investigate additional recurrence risks.
Collapse
Affiliation(s)
- B. Kipp
- grid.413354.40000 0000 8587 8621Department for Gynecologic Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - A. Vidal
- grid.413354.40000 0000 8587 8621Department for Gynecologic Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - D. Lenick
- grid.413354.40000 0000 8587 8621Department for Gynecologic Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - C. Christmann-Schmid
- grid.413354.40000 0000 8587 8621Department for Gynecologic Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| |
Collapse
|
3
|
Koh. Schwartz A, Vidal A, Fritsche L, Nirgianakis K, Vo. Wolff M, Mitter V. P–310 Women with endometriosis achieve live birth after a similar number of embryo transfers independent of the endometriosis subtype. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
How many embryo transfers are needed to achieve the first live birth in women with endometriosis depending on disease localisation?
Summary answer
The number of transfers needed to achieve live birth in women with endometriosis is independent from the disease’s subtype.
What is known already
Infertility is one of the leading symptoms in women with endometriosis. Endometriosis is also known to negatively impact in-vitro fertilization (IVF) outcome. A reduction of oocyte yield, especially of mature oocytes in women with endometrioma (OMA) and deep infiltrating endometriosis (DIE) has been shown. Inflammatory processes possibly affect folliculogenesis and oocyte development, maybe impeding embryo development and implantation. In contrast, even with fewer retrieved oocytes per cycle live birth rate was not affected. However, it is currently unknown if specific endometriosis subtypes could differentially affect IVF success. This would be relevant for a more targeted counseling regarding the treatment success.
Study design, size, duration
This is a single-center cohort study including women (N = 229) with embryo transfer cycles leading to live birth at the Bern University Hospital between 2010 and 2017. We only included women until they achieved the first live birth at our center. Participants/materials, setting, methods: We included 86 women with endometriosis and 143 women with male factor infertility serving as comparison group. We collected patient characteristics, details from the endometriosis surgery and reproductive treatment and outcomes from medical reports. We hierarchically classified the dominant endometriosis localizations as follows: deep infiltrating endometriosis (DIE, N = 21) > ovarian endometriosis (OMA, N = 35) > superficial peritoneal endometriosis (SUP, N = 30). We compared the number of embryo transfers needed to achieve a live birth.
Main results and the role of chance
Women with endometriosis were older (34.5 ± 3.9 years) than women from the control group (33.4 ± 3.9), p = 0.03. Body-mass-index, previous parity or Anti-Mullerian hormone level did not differ between the groups SUP, OMA, DIE or the comparison group. The number of necessary embryo transfer cycles to achieve a live birth did not differ between women with SUP (3.4 ± 2.6 embryo transfers), OMA (2.9 ± 2.0), DIE (3.0 ± 2.4) and the comparison group (2.9 ± 2.2), p = 0.59. IVF is beneficial in women with endometriosis, especially when OMA and/or DIE affect mobility of tubes and ovaries and spontaneous pregnancy is unlikely or impossible. This could account for the equal number of transfer cycles needed to achieve a live birth in women with OMA compared to the comparison group, even though the women with endometriosis were of older age. This is reassuring when counseling women with endometriosis.
Limitations, reasons for caution
We did not calculate cumulative pregnancy rate per cycle, because in Switzerland IVF treatment is at the patient’s own cost and therefore biased. We wanted to include all women with endometriosis, so fresh and thawing cycles were included. Women from the comparison group had no surgical exclusion of endometriosis.
Wider implications of the findings: Our study suggests that the endometriosis subtype does not determine the embryo transfer success rate after IVF and therefore is less relevant for counseling. Individualized anti-inflammatory treatment before embryo transfer might positively affect the cycles’ outcome. Studies with a larger sample are required to be more conclusive on this issue.
Trial registration number
BASEC 2015–00235
Collapse
Affiliation(s)
- A Koh. Schwartz
- Luzerner Kantonsspital, Division of Reproductive Medicine and Gyn. Endocrinology, Luzern, Switzerland
- Bern University Hospital Inselspital, Obstetrics and Gynecology- University of Bern, Bern, Switzerland
| | - A Vidal
- Luzerner Kantonsspital, Division of Reproductive Medicine and Gyn. Endocrinology, Luzern, Switzerland
| | - L Fritsche
- Bern University Hospital Inselspital, Obstetrics and Gynecology University of Bern, Bern, Switzerland
| | - K Nirgianakis
- Bern University Hospital Inselspital, Obstetrics and Gynecology University of Bern, Bern, Switzerland
| | - M Vo. Wolff
- Bern University Hospital Inselspital, Obstetrics and Gynecology University of Bern, Bern, Switzerland
| | - V Mitter
- Bern University Hospital Inselspital, Obstetrics and Gynecology University of Bern, Bern, Switzerland
- Norwegian Institute of Public Health, Folkshelseinstitut, Oslo, Norway
| |
Collapse
|
4
|
Vidal A, Dhakal C, Weiss J, Lehnick D, Koh. Schwartz A. P–654 What is the best luteal phase support in frozen-thawed embryo transfer cycle? Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
What is the best progesterone administration for luteal phase support (LPS) in frozen-thawed embryo transfer cycle?
Summary answer
Different modes of hormonal luteal phase support do not affect clinical pregnancy rate (CPR) or live birth rate (LBR) in frozen-thawed embryo transfer (FET) cycles.
What is known already
FET has increased substantially over the last years. To support implantation, endometrial and embryo maturities must be synchronized; therefore, endometrial and follicular maturation are monitored either within the artificial cycle. Estrogen and progesterone are sequentially administered. The optimal endometrial preparation strategy remains unclear; this study aims to compare the reproductive and pregnancy outcomes between five different regimens of hormonal LPS for FET treatment.
Study design, size, duration
Single centre retrospective cohort study conducted between 2013 and 2019. Included were women (N = 402) aged 18–45 years undergoing FET. After an optimal endometrial preparation and endometrial thickness, the LPS was started. Thereafter, five different progesterone applications were compared: (1) oral dydrogesterone (10mg tid), (2) vaginal progesterone gel (90mg/d), (3) dydrogesterone (10mg tid) plus vaginal progesterone gel (90mg/d), (4) vaginal progesterone capsules (200mg tid), or (5) subcutaneous injection of 25mg daily.
Participants/materials, setting, methods
An ultrasound was performed 14 days of estrogene ( > =4mg/d) preparation. If the endometrial thickness was ≥7 mm and there was no dominant follicle, luteal support commenced four days before FET. Fourteen days after transformation, a serum beta-hCG test was performed. If positive (> 50 IU/L), a transvaginal ultrasound was performed to confirm clinical pregnancy, defined as gestational sac with fetal heart movement. CPR was assessed and delivery reports for LBR were collected later.
Main results and the role of chance
In total, 402 patients on an artificial cycle were included (mean age, 35 years (y); range, 26–46 y; standard deviation, 4.1 y). No differences in endometrial thickness and cause of infertility were found between groups. Multivariate logistic regression analysis revealed that the odds ratios (ORs) with 95% confidence intervals (CIs) for the CPR was significantly higher in the dydrogesterone only group (OR, 3.25; 95% CI, 1.7–6.2; p < 0.001) and in the combined group (3) (OR, 7.55; 95% CI, 2.7–21.10; p < 0.001). Statistically significant differences in live birth rate could not be found between the five groups; they were 33%, 54%, 8.3%, 4%, 0% for groups 1, 2, 3, 4, and 5 respectively. Overall satisfaction and tolerability were significantly higher in oral dydrogesterone compared to the vaginal progesterone.
Limitations, reasons for caution
This is a retrospective single-center study. Also, potentially confounding variables like ethnicity, parity, BMI were not accounted for, possibly contributing to bias. Further prospective randomized studies are needed.
Wider implications of the findings: Oral dydrogesterone was found to be effective with equal CPR and LBR. Benefit is well-tolerated and accepted among patients; however we did not observe significant differences in the rates of live birth between the five regimens for used for LPS in women undergoing frozen-thawed embryo transfers.
Trial registration number
BASEC Switzerland 2020–01527
Collapse
Affiliation(s)
- A Vidal
- Lucerne Cantonal Hospital- Switzerland, Division of Gynecological Endocrinology and Reproductive Medicine-, Lucerne, Switzerland
| | - C Dhakal
- Lucerne Cantonal Hospital- Switzerland, Division of Gynecological Endocrinology and Reproductive Medicine-, Lucerne, Switzerland
| | - J Weiss
- VivaNeo Praxisklinik Sydow Berlin, Gynecological Endocrinology and Reproductive Medicine, Berlin, Germany
| | - D Lehnick
- University of Lucerne, Head Biostatistics and Methodology CTU-CS Clinical Trial Unit – Central, Berlin, Switzerland
| | - A Koh. Schwartz
- Lucerne Cantonal Hospital- Switzerland, Division of Gynecological Endocrinology and Reproductive Medicine-, Lucerne, Switzerland
| |
Collapse
|
5
|
Forouzandeh A, Blavi L, Abdelli N, Melo-Duran D, Vidal A, Rodríguez M, Monteiro ANTR, Pérez JF, Darwich L, Solà-Oriol D. Effects of dicopper oxide and copper sulfate on growth performance and gut microbiota in broilers. Poult Sci 2021; 100:101224. [PMID: 34157560 PMCID: PMC8237351 DOI: 10.1016/j.psj.2021.101224] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 03/04/2021] [Accepted: 04/14/2021] [Indexed: 01/04/2023] Open
Abstract
An experiment was conducted to determine the effects of two sources of copper (Cu) from copper sulfate (CuSO4) and dicopper oxide (Cu2O, CoRouge) at three levels of inclusion (15, 75, and 150 mg/kg) on growth performance and gut microbiota of broilers. A total of 840 one-d-old male chickens (Ross 308) were weighed and randomly allocated to seven dietary treatments: negative control (NC, a basal diet without Cu addition), and the NC supplemented with 15, 75, or 150 mg Cu/kg from CuSO4 or Cu2O (12 replicate pens/treatment, 10 chicks per pen). Broilers were challenged by reusing an old litter with high concentrations in Clostridium perfringens to promote necrotic enteritis. Broiler performance was registered at d 21, 35, and 42. Excreta samples were collected at d 14, 28, and 42 for antimicrobial resistance (AMR) analyses. At d 43, one broiler per pen was euthanized to obtain ileal content for microbial characterization. Body weight d 35 and daily gain d 42 improved (P < 0.05) in Cu2O as Cu dose inclusion increased from 15 mg/kg to 150 mg/kg. Supplementation of 150 mg/kg of Cu from Cu2O decreased the abundance (P < 0.01) of some families such as Streptococcaceae and Corynebacteriaceae and increased the abundance (P < 0.05) of some commensal bacteria like Clostridiaceae and Peptostreptococcaceae. Phenotypic AMR was not different among treatments on d 14 and 28. Isolated Enterococcus spp. from broilers fed the NC diet on d 42 showed higher (P < 0.05) resistance to enrofloxacin, gentamicin, and chloramphenicol compared with Cu treatments. By contrast, the isolated Escherichia coli from broilers fed 150 mg/kg of Cu, either from CuSO4 or Cu2O, showed higher (P < 0.05) resistance to streptomycin and chloramphenicol compared to the NC. This study suggests that supplementing 150 mg/kg of Cu from Cu2O establishes changes in the gut microbiota by regulating the bacterial population in the ileum, which may explain the positive impact on broilers' growth performance.
Collapse
Affiliation(s)
- A Forouzandeh
- Animal Nutrition and Welfare Service (SNiBA), Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - L Blavi
- Animal Nutrition and Welfare Service (SNiBA), Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
| | - N Abdelli
- Animal Nutrition and Welfare Service (SNiBA), Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - D Melo-Duran
- Animal Nutrition and Welfare Service (SNiBA), Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - A Vidal
- Department of Animal Health and Anatomy, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | | | | | - J F Pérez
- Animal Nutrition and Welfare Service (SNiBA), Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - L Darwich
- Department of Animal Health and Anatomy, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - D Solà-Oriol
- Animal Nutrition and Welfare Service (SNiBA), Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| |
Collapse
|
6
|
Vidal A, Adamo F, Iengo E, Alessio E. Models of molecular photocatalysts for water oxidation: Strategies for conjugating the Ru(bda) fragment (bda = 2,2′-bipyridine-6,6′-dicarboxylate) to porphyrin photosensitizers. Inorganica Chim Acta 2021. [DOI: 10.1016/j.ica.2020.120143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Olmo C, Franco L, Vidal A, del Valle LJ, Puiggali J. Ultrasound micromolding of porous polylactide/hydroxyapatite scaffolds. EXPRESS POLYM LETT 2021. [DOI: 10.3144/expresspolymlett.2021.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Angstwurm K, Vidal A, Stetefeld H, Dohmen C, Mergenthaler P, Kohler S, Schönenberger S, Bösel J, Neumann U, Lee DH, Gerner ST, Huttner HB, Thieme A, Dunkel J, Roth C, Schneider H, Schimmel E, Reichmann H, Fuhrer H, Berger B, Kleiter I, Schneider-Gold C, Alberty A, Zinke J, Schalke B, Steinbrecher A, Meisel A, Neumann B. Early Tracheostomy Is Associated With Shorter Ventilation Time and Duration of ICU Stay in Patients With Myasthenic Crisis-A Multicenter Analysis. J Intensive Care Med 2020; 37:32-40. [PMID: 33233998 DOI: 10.1177/0885066620967646] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Myasthenic crisis (MC) requiring mechanical ventilation (MV) is a rare and serious complication of myasthenia gravis. Here we analyzed the frequency of performed tracheostomies, risk factors correlating with a tracheostomy, as well as the impact of an early tracheostomy on ventilation time and ICU length of stay (LOS) in MC. METHODS Retrospective chart review on patients treated for MC in 12 German neurological departments between 2006 and 2015 to assess demographic/diagnostic data, rates and timing of tracheostomy and outcome. RESULTS In 107 out of 215 MC (49.8%), a tracheostomy was performed. Patients without tracheostomy were more likely to have an early-onset myasthenia gravis (27 [25.2%] vs 12 [11.5%], p = 0.01). Patients receiving a tracheostomy, however, were more frequently suffering from multiple comorbidities (20 [18.7%] vs 9 [8.3%], p = 0.03) and also the ventilation time (34.4 days ± 27.7 versus 7.9 ± 7.8, p < 0.0001) and ICU-LOS (34.8 days ± 25.5 versus 12.1 ± 8.0, p < 0.0001) was significantly longer than in non-tracheostomized patients. Demographics and characteristics of the course of the disease up to the crisis were not significantly different between patients with an early (within 10 days) compared to a late tracheostomy. However, an early tracheostomy correlated with a shorter duration of MV at ICU (26.2 days ± 18.1 versus 42.0 ± 33.1, p = 0.006), and ICU-LOS (26.2 days ± 14.6 versus 42.3 ± 33.0, p = 0.003). CONCLUSION Half of the ventilated patients with MC required a tracheostomy. Poorer health condition before the crisis and late-onset MG were associated with a tracheostomy. An early tracheostomy (≤ day 10), however, was associated with a shorter duration of MV and ICU-LOS by 2 weeks.
Collapse
Affiliation(s)
- Klemens Angstwurm
- Department of Neurology, University Medical Center Regensburg, Regensburg, Germany
| | - Amelie Vidal
- Department of Neurology, University Medical Center Regensburg, Regensburg, Germany
| | | | - Christian Dohmen
- Department of Neurology, University of Cologne, Cologne, Germany.,Department of Neurology, LVR-Klinik Bonn, Bonn, Germany
| | - Philipp Mergenthaler
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin.,Departments of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Siegfried Kohler
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin.,Berlin Institute of Health (BIH), Berlin, Germany
| | | | - Julian Bösel
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.,Department of Neurology, Klinikum Kassel, Kassel, Germany
| | - Ursula Neumann
- Department of Mathematics and Computer Science, Philipps-Universitaet Marburg, Marburg, Germany
| | - De-Hyung Lee
- Department of Neurology, University Medical Center Regensburg, Regensburg, Germany.,Department of Neurology, University Hospital Erlangen, Erlangen, Germany
| | - Stefan T Gerner
- Department of Neurology, University Hospital Erlangen, Erlangen, Germany
| | - Hagen B Huttner
- Department of Neurology, University Hospital Erlangen, Erlangen, Germany
| | - Andrea Thieme
- Department of Neurology, HELIOS Klinikum Erfurt, Erfurt, Germany
| | - Juliane Dunkel
- Department of Neurology, DRK-Kliniken Nordhessen, Kassel, Germany
| | - Christian Roth
- Department of Neurology, DRK-Kliniken Nordhessen, Kassel, Germany
| | - Hauke Schneider
- Department of Neurology, University Hospital, Technische Universität Dresden, Dresden, Germany.,Department of Neurology, University Hospital Augsburg, Augsburg, Germany
| | - Eik Schimmel
- Department of Neurology, University Hospital, Technische Universität Dresden, Dresden, Germany.,Department of Neurology, Staedtisches Klinikum Dresden, Dresden, Germany
| | - Heinz Reichmann
- Department of Neurology, University Hospital, Technische Universität Dresden, Dresden, Germany
| | - Hannah Fuhrer
- Department of Neurology, Medical Center-University of Freiburg, Germany
| | - Benjamin Berger
- Department of Neurology, Medical Center-University of Freiburg, Germany
| | - Ingo Kleiter
- Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.,Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany
| | | | - Anke Alberty
- Department of Neurology, Kliniken Maria Hilf GmbH Moenchengladbach, Mönchengladbach, Germany
| | - Jan Zinke
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - Berthold Schalke
- Department of Neurology, University Medical Center Regensburg, Regensburg, Germany
| | | | - Andreas Meisel
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin.,Departments of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Bernhard Neumann
- Department of Neurology, University Medical Center Regensburg, Regensburg, Germany
| |
Collapse
|
9
|
Kipp B, Vidal A, Braun C, Christmann C. Management of Borderline Ovarian Tumors (BOT): results of a retrospective, single center study in Switzerland. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- B Kipp
- Kantonsspital Luzern, Gynäkologie
| | - A Vidal
- Kantonsspital Luzern, Gynäkologie
| | - C Braun
- Kantonsspital Luzern, Gynäkologie
| | | |
Collapse
|
10
|
Vidal A, Frey J, Christmann C. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome and fecal Incontinence: A prospective Study. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Vidal
- Luzerner Kantonsspital, Frauenklinik
| | - J Frey
- Luzerner Kantonsspital, Frauenklinik
| | | |
Collapse
|
11
|
Vidal A, Kipp B, Christmann C. Vulvar Chron`s disease is a challenge: Case report. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Vidal
- Luzerner Kantonsspital, Frauenklinik
| | - B Kipp
- Luzerner Kantonsspital, Frauenklinik
| | | |
Collapse
|
12
|
Vidal A, Ardabili S, Hodel M. Conservative treatment of acute appendicitis in twin-pregnancy: a case report. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Vidal
- Luzerner Kantonsspital, Frauenklinik
| | | | - M Hodel
- Luzerner Kantonsspital, Frauenklinik
| |
Collapse
|
13
|
Vidal A, Fähnle I, Christmann C. Endometriosis cause a spontaneous Hemoperitoneum in a non-pregnant women after stopping Dienogest therapy: A case report. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Vidal
- Luzerner Kantonsspital, Frauenklinik
| | - I Fähnle
- Luzerner Kantonsspital, Frauenklinik
| | | |
Collapse
|
14
|
Marcoval J, Penín RM, Vidal A, Bermejo J. Extramammary Paget Disease. Actas Dermosifiliogr (Engl Ed) 2020; 111:306-312. [PMID: 32278442 DOI: 10.1016/j.ad.2019.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Revised: 08/09/2019] [Accepted: 09/15/2019] [Indexed: 10/24/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Extramammary Paget disease (EMPD) has seldom been studied in Mediterranean populations. We aimed to review the characteristics of our patients with EMPD, the presence of a neoplasm in continuity, and the long-term course of the disease. PATIENTS AND METHODS Retrospective observational study of 27 patients diagnosed with EMPD between 1990 and 2015. All clinical and pathology findings related to clinical course and outcomes were retrieved for analysis. RESULTS Twenty patients were women and 7 were men. Ages ranged from 42 to 88 years (median, 76 years). Lesions were in the following locations: vulva (16 cases), pubis-groin (5), perianal region (4), and axilla (2). Time from onset to diagnosis ranged from 1 to 60 months (median, 12 months) and maximum lesion diameter from 20 to 140mm (median, 55mm). In 3 cases (11.1%) EMPD was a secondary condition. None of the lesions developed on a previous cutaneous adnexal adenocarcinoma. Ten of the 24 primary EMPDs (41.7%) invaded the dermis. Eight of the 27 patients (29.6%) experienced local recurrence after the initial surgical treatment.Three patients (11.1%) died as a consequence of metastasis from the EMPD. CONCLUSIONS The presence of an underlying cutaneous adnexal adenocarcinoma is uncommon, but it is not unusual to find an extracutaneous adenocarcinoma in continuity. Although EMPD is a slow-growing tumor, dermal invasion is frequent and metastasis is not uncommon. Local recurrence is common even after excision with wide margins and may be delated, so long term follow-up is essential.
Collapse
Affiliation(s)
- J Marcoval
- Servicio de Dermatología, Hospital Universitari de Bellvitge, Barcelona, España.
| | - R M Penín
- Servicio de Anatomía Patológica, Hospital Universitari de Bellvitge, Barcelona, España
| | - A Vidal
- Servicio de Anatomía Patológica, Hospital Universitari de Bellvitge, Barcelona, España
| | - J Bermejo
- Servicio de Cirugía Plástica, Hospital Universitari de Bellvitge, Barcelona, España
| |
Collapse
|
15
|
Martins C, Vidal A, De Boevre M, De Saeger S, Nunes C, Torres D, Goios A, Lopes C, Alvito P, Assunção R. Burden of disease associated with dietary exposure to carcinogenic aflatoxins in Portugal using human biomonitoring approach. Food Res Int 2020; 134:109210. [PMID: 32517894 DOI: 10.1016/j.foodres.2020.109210] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 03/27/2020] [Accepted: 03/29/2020] [Indexed: 12/11/2022]
Abstract
Human biomonitoring is an important tool to assess human exposure to chemicals, contributing to describe trends of exposure over time and to identify population groups that could be under risk. Aflatoxins are genotoxic and carcinogenic food contaminants causing hepatocellular carcinoma, the third leading cause of cancer deaths worldwide. In Portugal, scarce data are available regarding exposure to aflatoxins and no previous study used human biomonitoring data to comprehensively characterize the associated burden of disease. 24 h urine and first-morning urine paired samples were collected by 94 participants and were analyzed by liquid chromatography-tandem mass spectrometry for the quantitative determination of aflatoxins (B1, B2, G1, G2 and M1). Deterministic and probabilistic models were developed to assess the Portuguese exposure to aflatoxins and to estimate the health impact of this exposure, estimating the attributed Disability-Adjusted Life Years (DALYs). Aflatoxins were detected in a maximum of 13% (AFB1), 16% (AFB2), 1% (AFG1), 2% (AFG2) and 19% (AFM1) of the urine samples. Data obtained through the probabilistic approach revealed an estimated mean probable daily intake of 13.43 ng/kg body weight per day resulting in 0.13 extra cases of hepatocellular carcinoma, corresponding to mean annual DALYs of 172.8 for the Portuguese population (10291027 inhabitants). The present study generated for the first time and within a human biomonitoring study, reliable and crucial data to characterize the burden associated to the exposure to aflatoxins of the Portuguese population. The obtained results constitute an imperative support to risk managers in the establishment of preventive policy measures that contribute to ensure public health protection.
Collapse
Affiliation(s)
- C Martins
- Food and Nutrition Department, National Institute of Health Dr. Ricardo Jorge, Avenida Padre Cruz, 1649-016 Lisboa, Portugal; NOVA National School of Public Health, Universidade NOVA de Lisboa, Avenida Padre Cruz, 1600-560 Lisboa, Portugal; CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; Public Health Research Centre, Universidade NOVA de Lisboa, Avenida Padre Cruz, 1600-560 Lisboa, Portugal.
| | - A Vidal
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
| | - M De Boevre
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
| | - S De Saeger
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
| | - C Nunes
- NOVA National School of Public Health, Universidade NOVA de Lisboa, Avenida Padre Cruz, 1600-560 Lisboa, Portugal; Public Health Research Centre, Universidade NOVA de Lisboa, Avenida Padre Cruz, 1600-560 Lisboa, Portugal
| | - D Torres
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Rua das Taipas 135, 4050-091 Porto, Portugal; Faculty of Nutrition and Food Sciences, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - A Goios
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Rua das Taipas 135, 4050-091 Porto, Portugal; Faculty of Nutrition and Food Sciences, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - C Lopes
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Rua das Taipas 135, 4050-091 Porto, Portugal; Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
| | - P Alvito
- Food and Nutrition Department, National Institute of Health Dr. Ricardo Jorge, Avenida Padre Cruz, 1649-016 Lisboa, Portugal; CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal
| | - R Assunção
- Food and Nutrition Department, National Institute of Health Dr. Ricardo Jorge, Avenida Padre Cruz, 1649-016 Lisboa, Portugal; CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal
| |
Collapse
|
16
|
Torras MG, Canals E, Muñoz-Montplet C, Vidal A, Jurado D, Eraso A, Villà S, Caro M, Molero J, Macià M, Puigdemont M, González-Muñoz E, López A, Guedea F, Borras JM. Improving quality of care and clinical outcomes for rectal cancer through clinical audits in a multicentre cancer care organisation. Radiat Oncol 2020; 15:28. [PMID: 32005123 PMCID: PMC6995177 DOI: 10.1186/s13014-020-1465-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 01/14/2020] [Indexed: 01/25/2023] Open
Abstract
Introduction Colorectal cancer treatment requires a complex, multidisciplinary approach. Because of the potential variability, monitoring through clinical audits is advisable. This study assesses the effects of a quality improvement action plan in patients with locally advanced rectal cancer and treated with radiotherapy. Methods Comparative, multicentre study in two cohorts of 120 patients each, selected randomly from patients diagnosed with rectal cancer who had initiated radiotherapy with a curative intent. Based on the results from a baseline clinical audit in 2013, a quality improvement action plan was designed and implemented; a second audit in 2017 evaluated its impact. Results Standardised information was present on 77.5% of the magnetic resonance imaging (MRI) staging reports. Treatment strategies were similar in all three study centres. Of the patients whose treatment was interrupted, just 9.7% received a compensation dose. There was an increase in MRI re-staging from 32.5 to 61.5%, and a significant decrease in unreported circumferential resection margins following neoadjuvant therapy (ypCRM), from 34.5 to 5.6% (p < 0.001). Conclusions The comparison between two clinical audits showed improvements in neoadjuvant radiotherapy in rectal cancer patients. Some indicators reveal areas in need of additional efforts, for example to reduce the overall treatment time.
Collapse
Affiliation(s)
- M G Torras
- Clinical Management Department, Institut Català d'Oncologia, Barcelona, Spain.
| | - E Canals
- Radiation Oncology Department, Institut Català d'Oncologia, Girona, Spain
| | - C Muñoz-Montplet
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - A Vidal
- Quality and Results Department, Institut Català d'Oncologia, Girona, Spain
| | - D Jurado
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - A Eraso
- Radiation Oncology Department, Institut Català d'Oncologia, Girona, Spain
| | - S Villà
- Radiation Oncology Department, Institut Català d'Oncologia, Badalona, Spain
| | - M Caro
- Radiation Oncology Department, Institut Català d'Oncologia, Badalona, Spain
| | - J Molero
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - M Macià
- Radiation Oncology Department, Institut Català d'Oncologia, Hospitalet del Llobregat, Barcelona, Spain
| | - M Puigdemont
- Hospital Tumor Registry, Institut Català d'Oncologia, Girona, Spain
| | - E González-Muñoz
- Quality and Results Department, Institut Català d'Oncologia, Girona, Spain
| | - A López
- Cancer Prevention and Control Program, Institut Català d'Oncologia, Hospitalet del Llobregat, Barcelona, Spain
| | - F Guedea
- Radiation Oncology Department, Institut Català d'Oncologia, Barcelona, Spain
| | - J M Borras
- Department of Clinical Sciences, IDIBELL, University of Barcelona, Barcelona, Spain
| |
Collapse
|
17
|
Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schönenberger S, Bösel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology 2019; 94:e299-e313. [PMID: 31801833 DOI: 10.1212/wnl.0000000000008688] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 07/11/2019] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVE To determine demographic characteristics, clinical features, treatment regimens, and outcome of myasthenic crisis (MC) requiring mechanical ventilation (MV). METHODS Analysis of patients who presented with MC between 2006 and 2015 in a German multicenter retrospective study. RESULTS We identified 250 cases in 12 participating centers. Median age at crisis was 72 years. Median duration of MV was 12 days. Prolonged ventilation (>15 days) depended on age (p = 0.0001), late-onset myasthenia gravis (MG), a high Myasthenia Gravis Foundation of America Class before crisis (p = 0.0001 for IVb, odds ratio [OR] = infinite), number of comorbidities (>3 comorbidities: p = 0.002, OR 2.99), pneumonia (p = 0.0001, OR 3.13), and resuscitation (p = 0.0008, OR 9.15). MV at discharge from hospital was necessary in 20.5% of survivors. Patients with early-onset MG (p = 0.0001, OR 0.21), thymus hyperplasia (p = 0.002, OR 0), and successful noninvasive ventilation trial were more likely to be ventilated for less than 15 days. Noninvasive ventilation in 92 cases was sufficient in 38%, which was accompanied by a significantly shorter duration of ventilation (p = 0.001) and intensive care unit (ICU) stay (p = 0.01). IV immunoglobulins, plasma exchange, and immunoadsorption were more likely to be combined sequentially if the duration of MV and the stay in an ICU extended (p = 0.0503, OR 2.05). Patients who received plasma exchange or immunoadsorption as first-line therapy needed invasive ventilation significantly less often (p = 0.003). In-hospital mortality was 12%, which was significantly associated with the number of comorbidities (>3) and complications such as acute respiratory distress syndrome and resuscitation. Main cause of death was multiorgan failure, mostly due to sepsis. CONCLUSION Mortality and duration of MC remained comparable to previous reports despite higher age and a high disease burden in our study. Prevention and treatment of complications and specialized neurointensive care are the cornerstones in order to improve outcome.
Collapse
Affiliation(s)
- Bernhard Neumann
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Klemens Angstwurm
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Philipp Mergenthaler
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Siegfried Kohler
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Silvia Schönenberger
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Julian Bösel
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Ursula Neumann
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Amelie Vidal
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Hagen B Huttner
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Stefan T Gerner
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Andrea Thieme
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Andreas Steinbrecher
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Juliane Dunkel
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Christian Roth
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Hauke Schneider
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Eik Schimmel
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Hannah Fuhrer
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Christine Fahrendorf
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Anke Alberty
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Jan Zinke
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Andreas Meisel
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Christian Dohmen
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany
| | - Henning R Stetefeld
- From the Department of Neurology (B.N., K.A., A.V.), University Medical Center Regensburg; NeuroCure Clinical Research Center (P.M., S.K., A.M.) and Departments of Neurology and Experimental Neurology (P.M., A.M.), Charité-Universitätsmedizin Berlin; Berlin Institute of Health (P.M., S.K., A.M.); Department of Neurology (S.S., J.B.), Heidelberg University Hospital; Department of Neurology (J.B.), Klinikum Kassel; Department of Mathematics and Computer Science (U.N.), Philipps-Universität Marburg; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology (A.T., A.S.), HELIOS Klinikum Erfurt; Department of Neurology (J.D., C.R.), DRK-Kliniken Nordhessen, Kassel; Department of Neurology (H.S., E.S.), University Hospital, Technische Universität Dresden; Department of Neurology (H.S.), Klinikum Augsburg; Department of Neurology (E.S.), Städtisches Klinikum Dresden; Department of Neurology (H.F.), University of Freiburg; Department of Neurology (C.F.), St. Josef-Hospital, Ruhr-University Bochum; Department of Neurology (A.A.), Kliniken Maria Hilf GmbH Mönchengladbach; Hans Berger Department of Neurology (J.Z.), Jena University Hospital; Department of Neurology (C.D., H.R.S.), University of Cologne; and Department of Neurology (C.D.), LVR-Klinik Bonn, Germany.
| | | |
Collapse
|
18
|
Martins C, Vidal A, De Boevre M, De Saeger S, Nunes C, Torres D, Goios A, Lopes C, Alvito P, Assunção R. Burden of disease attributable to exposure to aflatoxins in Portugal using Human biomonitoring data. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Human biomonitoring (HBM) is recognized as an important tool to assess the Human exposure to chemicals, contributing to describe trends and patterns of exposure over time and to identify population groups that could be under risk. Natural chemicals as mycotoxins, fungi metabolites that produce toxic effects in humans, are important compounds that could be found in foods usually consumed worldwide in a daily basis. Mycotoxins as aflatoxins (AFTs) are genotoxic, carcinogenic and immunosuppressive compounds. Hepatocellular carcinoma (HCC) is one of their main health toxic effects and is the third leading cause of cancer deaths worldwide. In Portugal, scarce data are available regarding exposure to AFTs and none previous study used HBM data to characterize comprehensively the burden associated to this exposure.
In the scope of the National Food, Nutrition, and Physical Activity Survey of the Portuguese General Population (2015-2016), 24h-urine samples from 94 participants were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) for the simultaneous determination of AFTs (B1, B2, G1, G2, M1). A model was developed to estimate the health impact of the exposure of Portuguese population to aflatoxins, estimating the number of cases of HCC and DALYs attributed to AFTs exposure.
AFTs were detected in 12.8% (AFB1), 16.0% (AFB2) and 19.1% (AFM1) of the 24h-urine samples. The estimated number of extra cases of HCC attributed to this exposure ranged from 17 to 65 cases/year; the associated DALYs for the Portuguese population ranged from 284 to 1802 years.
The present study generated, for the first time and within a HBM study, reliable data regarding the exposure of the Portuguese population to AFTs. These data were crucial to characterize the health impact associated to AFTs exposure and to support risk managers to establish preventive policy measures that contribute to ensure the public health protection.
Key messages
Portuguese population is exposed to aflatoxins, chemical food contaminants that may be harmful (carcinogenic, immunotoxic, mutagenic, teratogenic, hepatotoxic) to humans. Human biomonitoring studies provide realistic data on internal exposure at individual level, contributing to a more accurate estimation of the burden derived from this exposure.
Collapse
Affiliation(s)
- C Martins
- National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
- National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal
| | - A Vidal
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Portugal
| | - M De Boevre
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Portugal
| | - S De Saeger
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Portugal
| | - C Nunes
- National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal
| | - D Torres
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
- Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal
| | - A Goios
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
- Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal
| | - C Lopes
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
- Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal
| | - P Alvito
- National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal
| | - R Assunção
- National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal
| |
Collapse
|
19
|
Martins C, Vidal A, De Saeger S, Nunes C, Torres D, Goios A, Lopes C, Assunção R, Alvito P, De Boevre M. Risk assessment of Portuguese population to multiple mycotoxins: the human biomonitoring approach. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Mycotoxins constitute a relevant group of food contaminants with several associated health outcomes such as estrogenic, immunotoxic, nephrotoxic and teratogenic effects. Although scarce data are available in Portugal, human biomonitoring studies have been globally developed to assess the exposure to mycotoxins at individual level.
The present study concerned the analysis of mycotoxins in 24h urine and first-morning urine paired samples from 94 participants enrolled within the scope of the National Food, Nutrition, and Physical Activity Survey of the Portuguese General Population (2015-2016). Following a salt-assisted matrix extraction, urine samples were analyzed by liquid chromatography-mass spectrometry for the simultaneous determination of 37 urinary mycotoxins’ biomarkers and data obtained used to estimate the probable daily intake as well as the risk characterization applying the Hazard Quotient approach.
Results revealed the exposure of Portuguese population to zearalenone, deoxynivalenol, ochratoxin A, alternariol, citrinin and fumonisin B1 through the quantification in 24h urine and first-morning urine paired samples. Risk characterization data revealed a potential concern to some reported mycotoxins since the reference intake values were exceeded by some of the considered participants. Alternariol was identified for the first time in urine samples from a European country; however, risk characterization was not performed due to lack of reference intake value.
The present study contributed with reliable and evidence-based results, and confirmed that mycotoxins represent a burden and are part of the human exposome of the Portuguese population. Further studies are needed to shed a light on the determinants of exposure in order to contribute for the promotion of public health measures to reduce the mycotoxins’ exposure in Portugal.
Key messages
Portuguese population is exposed to mycotoxins, chemical food contaminants that may be harmful (carcinogenic, immunotoxic, mutagenic, teratogenic, hepatotoxic) for human health. Human biomonitoring studies provide realistic data on internal exposure at individual level, allowing a more accurate knowledge of the determinants of exposure to these contaminants.
Collapse
Affiliation(s)
- C Martins
- National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
- National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal
| | - A Vidal
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - S De Saeger
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - C Nunes
- National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal
| | - D Torres
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
- Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal
| | - A Goios
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
- Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal
| | - C Lopes
- Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
- Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal
| | - R Assunção
- National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal
| | - P Alvito
- National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal
| | - M De Boevre
- Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| |
Collapse
|
20
|
AlTurki A, Yuri P, Garcia D, Montemezzo M, Al-Dosari A, Vidal A, Toscani B, Diaz S, Bernier M, Hadjis T, Joza J, Essebag V. IMPROVED ELECTRICAL SYNCHRONY BY CARDIAC RESYNCHRONIZATION THERAPY REPROGRAMMING AND ECHOCARDIOGRAPHIC RESPONSE IN PATIENTS WITH EXISTING DEVICES. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
21
|
Martins C, Vidal A, De Boevre M, De Saeger S, Nunes C, Torres D, Goios A, Lopes C, Assunção R, Alvito P. Exposure assessment of Portuguese population to multiple mycotoxins: The human biomonitoring approach. Int J Hyg Environ Health 2019; 222:913-925. [DOI: 10.1016/j.ijheh.2019.06.010] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 04/18/2019] [Accepted: 06/24/2019] [Indexed: 12/11/2022]
|
22
|
De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, Kotseva K, De Backer G, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Bacquer DD, De Smedt D, De Sutter J, Deckers J, Dilic M, Dolzhenko M, Druais H, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Grobbee D, Gyberg V, Hasan Ali H, Heuschmann P, Hoes A, Jankowski P, Lalic N, Lehto S, Lovic D, Maggioni A, Mancas S, Marques-Vidal P, Mellbin L, Miličić D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Ž, Rydén L, Stagmo M, Störk S, Sundvall J, Tokgözoğlu L, Tsioufis K, Vulic D, Wood D, Wood D, Kotseva K, Jennings C, Adamska A, Adamska S, Rydén L, Mellbin L, Tuomilehto J, Schnell O, Druais H, Fiorucci E, Glemot M, Larras F, Missiamenou V, Maggioni A, Taylor C, Ferreira T, Lemaitre K, Bacquer DD, De Backer G, Raman L, Sundvall J, DeSmedt D, De Sutter J, Willems A, De Pauw M, Vervaet P, Bollen J, Dekimpe E, Mommen N, Van Genechten G, Dendale P, Bouvier C, Chenu P, Huyberechts D, Persu A, Dilic M, Begic A, Durak Nalbantic A, Dzubur A, Hadzibegic N, Iglica A, Kapidjic S, Osmanagic Bico A, Resic N, Sabanovic Bajramovic N, Zvizdic F, Vulic D, Kovacevic-Preradovic T, Popovic-Pejicic S, Djekic D, Gnjatic T, Knezevic T, Kovacevic-Preradovic T, Kos L, Popovic-Pejicic S, Stanetic B, Topic G, Gotcheva N, Georgiev B, Terziev A, Vladimirov G, Angelov A, Kanazirev B, Nikolaeva S, Tonkova D, Vetkova M, Milicic D, Reiner Ž, Bosnic A, Dubravcic M, Glavina M, Mance M, Pavasovic S, Samardzic J, Batinic T, Crljenko K, Delic-Brkljacic D, Dula K, Golubic K, Klobucar I, Kordic K, Kos N, Nedic M, Olujic D, Sedinic V, Blazevic T, Pasalic A, Percic M, Sikic J, Bruthans J, Cífková R, Hašplová K, Šulc P, Wohlfahrt P, Mayer O, Cvíčela M, Filipovský J, Gelžinský J, Hronová M, Hasan-Ali H, Bakery S, Mosad E, Hamed H, Ibrahim A, Elsharef M, Kholef E, Shehata A, Youssef M, Elhefny E, Farid H, Moustafa T, Sobieh M, Kabil H, Abdelmordy A, Lehto S, Kiljander E, Kiljander P, Koukkunen H, Mustonen J, Cremer C, Frantz S, Haupt A, Hofmann U, Ludwig K, Melnyk H, Noutsias M, Karmann W, Prondzinsky R, Herdeg C, Hövelborn T, Daaboul A, Geisler T, Keller T, Sauerbrunn D, Walz-Ayed M, Ertl G, Leyh R, Störk S, Heuschmann P, Ehlert T, Klocke B, Krapp J, Ludwig T, Käs J, Starke C, Ungethüm K, Wagner M, Wiedmann S, Tsioufis K, Tolis P, Vogiatzi G, Sanidas E, Tsakalis K, Kanakakis J, Koutsoukis A, Vasileiadis K, Zarifis J, Karvounis C, Crowley J, Gibson I, Houlihan A, Kelly C, O'Donnell M, Bennati M, Cosmi F, Mariottoni B, Morganti M, Cherubini A, Di Lenarda A, Radini D, Ramani F, Francese M, Gulizia M, Pericone D, Davletov K, Aigerim K, Zholdin B, Amirov B, Assembekov B, Chernokurova E, Ibragimova F, Kodasbayev A, Markova A, Mirrakhimov E, Asanbaev A, Toktomamatov U, Tursunbaev M, Zakirov U, Abilova S, Arapova R, Bektasheva E, Esenbekova J, Neronova K, Asanbaev A, Baigaziev K, Toktomamatov U, Zakirov U, Baitova G, Zheenbekov T, Erglis A, Andrejeva T, Bajare I, Kucika G, Labuce A, Putane L, Stabulniece M, Dzerve V, Klavins E, Sime I, Badariene J, Gedvilaite L, Pečiuraite D, Sileikienė V, Skiauteryte E, Solovjova S, Sidabraite R, Briedis K, Ceponiene I, Jurenas M, Kersulis J, Martinkute G, Vaitiekiene A, Vasiljevaite K, Veisaite R, Plisienė J, Šiurkaitė V, Vaičiulis Ž, Jankowski P, Czarnecka D, Kozieł P, Podolec P, Nessler J, Gomuła P, Mirek-Bryniarska E, Bogacki P, Wiśniewski A, Pająk A, Wolfshaut-Wolak R, Bućko J, Kamiński K, Łapińska M, Paniczko M, Raczkowski A, Sawicka E, Stachurska Z, Szpakowicz M, Musiał W, Dobrzycki S, Bychowski J, Kosior D, Krzykwa A, Setny M, Kosior D, Rak A, Gąsior Z, Haberka M, Gąsior Z, Haberka M, Szostak-Janiak K, Finik M, Liszka J, Botelho A, Cachulo M, Sousa J, Pais A, Aguiar C, Durazzo A, Matos D, Gouveia R, Rodrigues G, Strong C, Guerreiro R, Aguiar J, Abreu A, Cruz M, Daniel P, Morais L, Moreira R, Rosa S, Rodrigues I, Selas M, Gaita D, Mancas S, Apostu A, Cosor O, Gaita L, Giurgiu L, Hudrea C, Maximov D, Moldovan B, Mosteoru S, Pleava R, Ionescu M, Parepa I, Pogosova N, Arutyunov A, Ausheva A, Isakova S, Karpova A, Salbieva A, Sokolova O, Vasilevsky A, Pozdnyakov Y, Antropova O, Borisova L, Osipova I, Lovic D, Aleksic M, Crnokrak B, Djokic J, Hinic S, Vukasin T, Zdravkovic M, Lalic N, Jotic A, Lalic K, Lukic L, Milicic T, Macesic M, Stanarcic Gajovic J, Stoiljkovic M, Djordjevic D, Kostic S, Tasic I, Vukovic A, Fras Z, Jug B, Juhant A, Krt A, Kugonjič U, Chipayo Gonzales D, Gómez Barrado J, Kounka Z, Marcos Gómez G, Mogollón Jiménez M, Ortiz Cortés C, Perez Espejo P, Porras Ramos Y, Colman R, Delgado J, Otero E, Pérez A, Fernández-Olmo M, Torres-LLergo J, Vasco C, Barreñada E, Botas J, Campuzano R, González Y, Rodrigo M, de Pablo C, Velasco E, Hernández S, Lozano C, González P, Castro A, Dalmau R, Hernández D, Irazusta F, Vélez A, Vindel C, Gómez-Doblas J, García Ruíz V, Gómez L, Gómez García M, Jiménez-Navarro M, Molina Ramos A, Marzal D, Martínez G, Lavado R, Vidal A, Rydén L, Boström-Nilsson V, Kjellström B, Shahim B, Smetana S, Hansen O, Stensgaard-Nake E, Deckers J, Klijn A, Mangus T, Peters R, Scholte op Reimer W, Snaterse M, Aydoğdu S, Ç Erol, Otürk S, Tulunay Kaya C, Ahmetoğlu Y, Ergene O, Akdeniz B, Çırgamış D, Akkoyun H Kültürsay S, Kayıkçıoğlu M, Çatakoğlu A, Çengel A, Koçak A, Ağırbaşlı M, Açıksarı G, Çekin M, Tokgözoğlu L, Kaya E, Koçyiğit D, Öngen Z, Özmen E, Sansoy V, Kaya A, Oktay V, Temizhan A, Ünal S, İ Yakut, Kalkan A, Bozkurt E, Kasapkara H, Dolzhenko M, Faradzh C, Hrubyak L, Konoplianyk L, Kozhuharyova N, Lobach L, Nesukai V, Nudchenko O, Simagina T, Yakovenko L, Azarenko V, Potabashny V, Bazylevych A, Bazylevych M, Kaminska K, Panchenko L, Shershnyova O, Ovrakh T, Serik S, Kolesnik T, Kosova H, Wood D, Adamska A, Adamska S, Jennings C, Kotseva K, Hoye P Atkin A, Fellowes D, Lindsay S, Atkinson C, Kranilla C, Vinod M, Beerachee Y, Bennett C, Broome M, Bwalya A, Caygill L, Dinning L, Gillespie A, Goodfellow R, Guy J, Idress T, Mills C, Morgan C, Oustance N, Singh N, Yare M, Jagoda J, Bowyer H, Christenssen V, Groves A, Jan A, Riaz A, Gill M, Sewell T, Gorog D, Baker M, De Sousa P, Mazenenga T, Porter J, Haines F, Peachey T, Taaffe J, Wells K, Ripley D, Forward H, McKie H, Pick S, Thomas H, Batin P, Exley D, Rank T, Wright J, Kardos A, Sutherland SB, Wren L, Leeson P, Barker D, Moreby B, Sawyer J, Stirrup J, Brunton M, Brodison A, Craig J, Peters S, Kaprielian R, Bucaj A, Mahay K, Oblak M, Gale C, Pye M, McGill Y, Redfearn H, Fearnley M. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285:135-146. [DOI: 10.1016/j.atherosclerosis.2019.03.014] [Citation(s) in RCA: 101] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 02/22/2019] [Accepted: 03/19/2019] [Indexed: 12/16/2022]
|
23
|
Martins C, De Boevre M, De Saeger S, Assunção R, Nunes C, Torres D, Goios A, Lopes C, Alvito P, Vidal A. Exposure of Portuguese population to mycotoxins: the contribution of human biomonitoring studies. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C Martins
- National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
- NOVA National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Lisbon, Portugal
| | - M De Boevre
- Laboratory of Food Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - S De Saeger
- Laboratory of Food Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - R Assunção
- National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Lisbon, Portugal
| | - C Nunes
- NOVA National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal
| | - D Torres
- Faculty of Nutrition and Food Sciences, University of Porto; Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
| | - A Goios
- Faculty of Nutrition and Food Sciences, University of Porto; Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
| | - C Lopes
- Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto; Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
| | - P Alvito
- National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
- CESAM, Centre for Environmental and Marine Studies, University of Aveiro, Lisbon, Portugal
| | - A Vidal
- Laboratory of Food Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| |
Collapse
|
24
|
Gonçalves-Ribeiro S, Sanz-Pamplona R, Vidal A, Sanjuan X, Guillen Díaz-Maroto N, Soriano A, Guardiola J, Albert N, Martínez-Villacampa M, López I, Santos C, Serra-Musach J, Salazar R, Capellà G, Villanueva A, Molleví DG. Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. Ann Oncol 2018; 28:2160-2168. [PMID: 28911071 DOI: 10.1093/annonc/mdx293] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Preoperative chemoradiotherapy followed by surgical mesorectal resection is the standard of care for locally advanced rectal carcinomas. Yet, predicting that patients will respond to treatment remains an unmet clinical challenge. Experimental design Using laser-capture microdissection we isolated RNA from stroma and tumour glands from prospective pre-treatment samples (n = 15). Transcriptomic profiles were obtained hybridising PrimeView Affymetrix arrays. We modelled a carcinoma-associated fibroblast-specific genes filtering data using GSE39396. Results The analysis of differentially expressed genes of stroma/tumour glands from responder and non-responder patients shows that most changes were associated with the stromal compartment; codifying mainly for extracellular matrix and ribosomal components. We built a carcinoma-associated fibroblast (CAF) specific classifier with genes showing changes in expression according to the tumour regression grade (FN1, COL3A1, COL1A1, MMP2 and IGFBP5). We assessed these five genes at the protein level by means of immunohistochemical staining in a patient's cohort (n = 38). For predictive purposes we used a leave-one-out cross-validated model with a positive predictive value (PPV) of 83.3%. Random Forest identified FN1 and COL3A1 as the best predictors. Rebuilding the leave-one-out cross-validated regression model improved the classification performance with a PPV of 93.3%. An independent cohort was used for classifier validation (n = 36), achieving a PPV of 88.2%. In a multivariate analysis, the two-protein classifier proved to be the only independent predictor of response. Conclusion We developed a two-protein immunohistochemical classifier that performs well at predicting the non-response to neoadjuvant treatment in rectal cancer.
Collapse
Affiliation(s)
| | - R Sanz-Pamplona
- Program of Prevention and Cancer Control, Biomarkers Unit, Catalan Institute of Oncology
| | | | | | | | - A Soriano
- Department of Gastroenterology Endoscopy Unit, Hospital Universitari de Bellvitge
| | - J Guardiola
- Department of Gastroenterology Endoscopy Unit, Hospital Universitari de Bellvitge
| | - N Albert
- Program Against Cancer Therapeutic Resistance
| | | | - I López
- Department of Medical Oncology
| | | | | | | | - G Capellà
- Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain
| | | | - D G Molleví
- Program Against Cancer Therapeutic Resistance
| |
Collapse
|
25
|
Pino F, Stevanato L, Fabris D, Barros H, Vidal A, Nebbia G, Lunardon M, Moretto S, Sajo-Bohus L. A compact equipment for the sulfur content estimation in heavy oil using neutrons and gamma-rays. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201817007006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
|
27
|
Anadón C, van Tetering G, Ferreira HJ, Moutinho C, Martínez-Cardús A, Villanueva A, Soler M, Heyn H, Moran S, Castro de Moura M, Setien F, Vidal A, Genescà E, Ribera JM, Nomdedeu JF, Guil S, Esteller M. Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia. Leukemia 2017; 31:1622-1625. [PMID: 28344317 PMCID: PMC5501321 DOI: 10.1038/leu.2017.99] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- C Anadón
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - G van Tetering
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - H J Ferreira
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - C Moutinho
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - A Martínez-Cardús
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - A Villanueva
- Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - M Soler
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - H Heyn
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - S Moran
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - M Castro de Moura
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - F Setien
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - A Vidal
- Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - E Genescà
- Hematology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - J M Ribera
- Hematology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - J F Nomdedeu
- Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Guil
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - M Esteller
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.,Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.,Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| |
Collapse
|
28
|
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene 2016; 36:2737-2749. [PMID: 27991928 PMCID: PMC5442428 DOI: 10.1038/onc.2016.427] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 08/31/2016] [Accepted: 10/10/2016] [Indexed: 01/16/2023]
Abstract
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Collapse
Affiliation(s)
- F Mateo
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - E J Arenas
- Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
| | - H Aguilar
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Serra-Musach
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - G Ruiz de Garibay
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Boni
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Maicas
- Centre for Applied Medical Research (CIMA) and Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
| | - S Du
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - F Iorio
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.,Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - C Herranz-Ors
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Islam
- Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh
| | - X Prado
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Llorente
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Petit
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Vidal
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Català
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - T Soler
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - G Venturas
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Rojo-Sebastian
- Department of Pathology, MD Anderson Cancer Center, Madrid, Spain
| | - H Serra
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - D Cuadras
- Statistics Unit, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Blanco
- Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Lozano
- Department of Molecular Biology and Biochemistry, Málaga University, and Molecular Oncology Laboratory, Mediterranean Institute for the Advance of Biotechnology and Health Research (IBIMA), University Hospital Virgen de la Victoria, Málaga, Spain
| | - F Canals
- ProteoRed-Instituto de Salud Carlos III, Proteomic Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain
| | - A M Sieuwerts
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - V de Weerd
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - M P Look
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - S Puertas
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - N García
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A S Perkins
- University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY, USA
| | - N Bonifaci
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Skowron
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - L Gómez-Baldó
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - V Hernández
- Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Martínez-Aranda
- Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Martínez-Iniesta
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - X Serrat
- Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - J Cerón
- Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - J Brunet
- Hereditary Cancer Programme, ICO, Girona Biomedical Research Institute (IDIBGI), Girona, Spain
| | - M P Barretina
- Department of Medical Oncology, ICO, IDIBGI, Girona, Spain
| | - M Gil
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - C Falo
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Fernández
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Morilla
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - S Pernas
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M J Plà
- Department of Gynecology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - X Andreu
- Department of Pathology, Parc Taulí Hospital Consortium, Sabadell, Barcelona, Spain
| | - M A Seguí
- Medical Oncology Service, Parc Taulí Hospital Consortium, Sabadell, Barcelona, Spain
| | - R Ballester
- Department of Radiation Oncology, University Hospital Germans Trias i Pujol, ICO, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
| | - E Castellà
- Department of Pathology, University Hospital Germans Trias i Pujol, ICO, IGTP, Badalona, Barcelona, Spain
| | - M Nellist
- Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - S Morales
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - J Valls
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - A Velasco
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - X Matias-Guiu
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - A Figueras
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J V Sánchez-Mut
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Sánchez-Céspedes
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Cordero
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Gómez-Miragaya
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - L Palomero
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Gómez
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - T F Gajewski
- Departments of Pathology and Medicine, University of Chicago, Chicago, IL, USA
| | - E E W Cohen
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - M Jesiotr
- Department of Pathology, Military Institute of Medicine, Warsaw, Poland
| | - L Bodnar
- Department of Oncology, Military Institute of Medicine, Warsaw, Poland
| | - M Quintela-Fandino
- Breast Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain
| | - N López-Bigas
- Department of Experimental and Health Sciences, Barcelona Biomedical Research Park, Pompeu Fabra University (UPF), Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - R Valdés-Mas
- Department of Biochemistry and Molecular Biology, University Institute of Oncology of Asturias, University of Oviedo, Oviedo, Spain
| | - X S Puente
- Department of Biochemistry and Molecular Biology, University Institute of Oncology of Asturias, University of Oviedo, Oviedo, Spain
| | - F Viñals
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - O Casanovas
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Graupera
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Hernández-Losa
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - S Ramón Y Cajal
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - L García-Alonso
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK
| | - J Saez-Rodriguez
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK
| | - M Esteller
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.,Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain
| | - A Sierra
- Molecular and Translational Oncology Laboratory, Biomedical Research Center CELLEX-CRBC, Biomedical Research Institute 'August Pi i Sunyer' (IDIBAPS), and Systems Biology Department, Faculty of Science and Technology, University of Vic, Central University of Catalonia, Barcelona, Spain
| | - N Martín-Martín
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain
| | - A Matheu
- Neuro-Oncology Section, Oncology Department, Biodonostia Research Institute, San Sebastian, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| | - A Carracedo
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain.,Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Bilbao, Spain
| | - E González-Suárez
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Nanjundan
- Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, USA
| | - J Cortés
- Department of Medical Oncology, VHIO, Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Lázaro
- Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M D Odero
- Centre for Applied Medical Research (CIMA) and Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
| | - J W M Martens
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - G Moreno-Bueno
- Department of Biochemistry, Autonomous University of Madrid (UAM), Biomedical Research Institute 'Alberto Sols' (Spanish National Research Council (CSIC)-UAM), Translational Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), and MD Anderson International Foundation, Madrid, Spain
| | - M H Barcellos-Hoff
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - A Villanueva
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - R R Gomis
- Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - M A Pujana
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| |
Collapse
|
29
|
Vidal A, Cano-Sancho G, Marín S, Ramos A, Sanchis V. Multidetection of urinary ochratoxin A, deoxynivalenol and its metabolites: pilot time-course study and risk assessment in Catalonia, Spain. WORLD MYCOTOXIN J 2016. [DOI: 10.3920/wmj2015.2006] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The presence of two main mycotoxins, ochratoxin A (OTA) and deoxynivalenol (DON), is widespread in cereal-based foodstuffs marketed in Europe. The objectives of this study were to develop and validate a multi-detection analytical methodology to simultaneously assess the urinary concentrations of OTA, DON and their metabolites, and to apply this methodology in a preliminary follow-up trial in Catalonia (Spain). Hence, an ultra-performance liquid chromatography with tandem mass spectrometry method was developed to simultaneously assess the urinary levels of OTA, DON, deoxynivalenol-3-glucoside (DON-3-glucoside), deoxynivalenol-3-glucuronide (DON-3-glucuronide), 3-acetyldeoxynivalenol (3-ADON) and de-epoxy-deoxynivalenol (DOM-1). Urine mycotoxins levels and food dietary intake were prospectively monitored in a group of volunteers throughout a restriction period followed by a free-diet period. The proposed multi-detection methodology for urinary OTA and DON metabolites was validated, providing suitable recovery, linearity and precision. The results from the pilot trial showed that urinary OTA, DON and its metabolites were detected in most background samples, displaying moderate reductions after the restriction period and subsequently recovering the background levels. Despite the restriction period, some DON metabolites, such as 3-ADON or DOM-1, were still found in urine samples, placing alternative sources of DON exposure other than the ones considered in the study under suspicion. DON and DON-3-glucuronide were significantly associated with consumption of bread, pasta and pastries, while OTA was only associated with consumption of wine and breakfast cereals. The urinary levels of OTA were significantly correlated with plasmatic levels of OTA and ochratoxin α, supporting the results from the multidetection method in urine. The results also showed that the high exposure to DON could be held throughout the time by the same person, exceeding the tolerable daily intake systematically instead of eventually. The estimates of OTA exposure through urine are largely higher than those obtained with the dietary approach. The background levels found in urine revealed that the exposure to DON and OTA could be of concern for the Catalonian population, thus, further studies applying this biomonitoring methodology in a larger sample of Catalonian population are needed to accurately characterise the human health risks at population level.
Collapse
Affiliation(s)
- A. Vidal
- Food Technology Department, XaRTA-UTPV, Agrotecnio Center, University of Lleida, Av. Rovira Roure 191, 25198 Lleida, Spain
| | - G. Cano-Sancho
- Department of Environmental Toxicology, University of California at Davis, One Shields Avenue, Davis, CA 95616-8627, USA
| | - S. Marín
- Department of Environmental Toxicology, University of California at Davis, One Shields Avenue, Davis, CA 95616-8627, USA
| | - A.J. Ramos
- Food Technology Department, XaRTA-UTPV, Agrotecnio Center, University of Lleida, Av. Rovira Roure 191, 25198 Lleida, Spain
| | - V. Sanchis
- Food Technology Department, XaRTA-UTPV, Agrotecnio Center, University of Lleida, Av. Rovira Roure 191, 25198 Lleida, Spain
| |
Collapse
|
30
|
Velasquez T, Mackey G, Lusk J, Kyle UG, Fontenot T, Marshall P, Shekerdemian LS, Coss-Bu JA, Nishigaki A, Yatabe T, Tamura T, Yamashita K, Yokoyama M, Ruiz-Rodriguez JC, Encina B, Belmonte R, Troncoso I, Tormos P, Riveiro M, Baena J, Sanchez A, Bañeras J, Cordón J, Duran N, Ruiz A, Caballero J, Nuvials X, Riera J, Serra J, Rutten AMF, van Ieperen SNM, Der Kinderen EPHM, Van Logten T, Kovacikova L, Skrak P, Zahorec M, Kyle UG, Akcan-Arikan A, Silva JC, Mackey G, Lusk J, Goldsworthy M, Shekerdemian LS, Coss-Bu JA, Wood D, Harrison D, Parslow R, Davis P, Pappachan J, Goodwin S, Ramnarayan P, Chernyshuk S, Yemets H, Zhovnir V, Pulitano’ SM, De Rosa S, Mancino A, Villa G, Tosi F, Franchi P, Conti G, Patel B, Khine H, Shah A, Sung D, Singer L, Haghbin S, Inaloo S, Serati Z, Idei M, Nomura T, Yamamoto N, Sakai Y, Yoshida T, Matsuda Y, Yamaguchi Y, Takaki S, Yamaguchi O, Goto T, Longani N, Medar S, Abdel-Aal IR, El Adawy AS, Mohammed HMEH, Mohamed AN, Parry SM, Knight LD, Denehy L, De Morton N, Baldwin CE, Sani D, Kayambu G, da Silva VZM, Phongpagdi P, Puthucheary ZA, Granger CL, Rydingsward JE, Horkan CM, Christopher KB, Muscedere J, Scott SH, Saha T, Hamilton A, Petsikas D, Payne D, Boyd JG, Puthucheary ZA, McNelly AS, Rawal J, McWilliams D, Connolly B, McPhail MJ, Sidhu P, Rowlerson A, Moxham J, Harridge SD, Hart N, Montgomery HE, Jovaisa T, Thomas B, Jones C, Gupta D, Wijayatilake DS, Shum HP, King HS, Chan KC, Tang KB, Yan WW, Arias CC, Latorre J, De La Rica AS, Reeves E, Garrido EM, Feijoo AM, Gancedo CH, Tofiño AL, Rodríguez FG, Gemmell LK, Campbell R, Doherty P, MacKay A, Singh N, Atkins G, Vitaller S, Nagib H, Prieto J, Del Arco A, Zayas B, Gomez C, Tirumala S, Pasha SA, Kumari BK, Martinez-Lopez P, Snelson C, Puerto-Morlán A, Nuevo-Ortega P, Pujol LM, Dolset RA, González BS, Riera SQ, Álvarez JT, Quintana S, Martínez L, Algarte R, Aitken LM, Sánchez B, Trenado J, Tomas E, Brock N, Viegas E, Filipe E, Cottle D, Traynor T, Martínez MVT, Márquez MP, Rattray J, Gómez LC, Martínez NA, Muñoz JMM, Bellver BQ, Varea MM, Llorente MÁA, Calvo CP, Hillier SD, Faulds MC, Hendra H, Kenardy J, Lawrence N, Maekawa K, Hayakawa M, Ono Y, Kodate A, Sadamoto Y, Tominaga N, Mizugaki A, Murakami H, Yoshida T, Hull AM, Katabami K, Wada T, Sawamura A, Gando S, Silva S, Kerhuel L, Malagurski B, Citerio G, Chabanne R, Laureys S, Ullman A, Puybasset L, Nobile L, Pognuz ER, Rossetti AO, Verginella F, Gaspard N, Creteur J, Ben-Hamouda N, Oddo M, Taccone FS, Le Brocque R, Ono Y, Hayakawa M, Iijima H, Maekawa K, Kodate A, Sadamoto Y, Mizugaki A, Murakami H, Katabami K, Wada T, Mitchell M, Sawamura A, Gando S, Kodate A, Katabami K, Wada T, Ono Y, Maekawa K, Hayakawa M, Sawamura A, Gando S, Davis C, Andersen LW, Raymond T, Berg R, Nadkarni V, Grossestreuer A, Kurth T, Donnino M, Krüger A, Ostadal P, Janotka M, Macfarlane B, Vondrakova D, Kongpolprom N, Cholkraisuwat J, Pekkarinen PT, Ristagno G, Masson S, Latini R, Bendel S, Ala-Kokko T, Varpula T, Azevedo JC, Vaahersalo J, Hoppu S, Tiainen M, Mion MM, Plebani M, Pettilä V, Skrifvars M, Son Y, Kim KS, Suh GJ, Rocha LL, Kwon WY, Ko JI, Park MJ, Cavicchi FZ, Iesu E, Nobile L, Vincent JL, Creteur J, Taccone FS, Tanaka H, De Freitas FFM, Otani N, Ode S, Ishimatsu S, Martínez L, Algarte R, Sánchez B, Romero I, Martínez F, Quintana S, Trenado J, Cavalheiro AM, Vondrakova D, Ostadal P, Kruger A, Janotka M, Malek F, Neuzil P, Yeh YC, Chen YS, Wang CH, Huang CH, Lucinio NM, Chao A, Lee CT, Lai CH, Chan WS, Cheng YJ, Sun WZ, Kaese S, Horstmann C, Lebiedz P, Mourad M, Lobato MS, Gaudard P, Eliet J, Zeroual N, Colson P, Ostadal P, Mlcek M, Hrachovina M, Kruger A, Vondrakova D, Janotka M, Ebeling G, Mates M, Hala P, Kittnar O, Neuzil P, Jacky A, Rudiger A, Spahn DR, Bettex DA, Kara A, Akin S, Kraegpoeth A, Dos reis Miranda D, Struijs A, Caliskan K, van Thiel RJ, Dubois EA, de Wilde W, Zijlstra F, Gommers D, Ince C, Marca L, Laerkner E, Xini A, Mongkolpun W, Cordeiro CPR, Leite RT, Lheureux O, Bader A, Rincon L, Santacruz C, Preiser JC, Chao A, De Brito-Ashurst I, Chao AS, Chen YS, Kim W, Ahn C, Cho Y, Lim TH, Oh J, Choi KS, Jang BH, Ha JK, White C, Mecklenburg A, Stamm J, Soeffker G, Kubik M, Sydow K, Reichenspurner H, Kluge S, Braune S, Bergantino B, Ruberto F, Gregory S, Magnanimi E, Privato E, Zullino V, Bruno K, Pugliese F, Sales G, Girotto V, Vittone F, Brazzi L, Fritz C, Forni LG, Kimmoun A, Vanhuyse F, Trifan B, Orlowski S, Albuisson E, Tran N, Levy B, Chhor V, Joachim J, Follin A, Flowers E, Champigneulle B, Chatelon J, Fave G, Mantz J, Pirracchio R, Diaz DD, Villanova M, Aguirregabyria M, Andrade G, López L, Curtis A, Palencia E, John G, Cowan R, Hart R, Lake K, Litchfield K, Song JW, Lee YJ, Cho YJ, Choi S, Wood CA, Vermeir P, Vandijck D, Blot S, Mariman A, Verhaeghe R, Deveugele M, Vogelaers D, Chok L, Bachli EB, Bettex D, Siu K, Cottini SR, Keller E, Maggiorini M, Schuepbach R, Fiks T, Stiphout C, Grevelink M, Vaneker I, Ruijter A, Buise M, Venkatesan K, Spronk PE, Tena SA, Barrachina LG, Portillo JHR, Aznar GP, Campos LM, Sellés MDF, Tomás MA, Muncharaz AB, Skinner L, Muhammad JBH, Monsalvo S, Olavarria E, Stümpfle R, Na SJ, Park J, Chung CR, Park CM, Suh GY, Yang JH, Witter T, Ng L, Brousseau C, Butler MB, Erdogan M, Dougall PCM, Green RS, Abbott TEF, Torrance HDT, Cron N, Vaid N, Emmanuel J, Seet E, Siddiqui SS, Prabu N, Chaudhari HK, Patil VP, Divatia JV, Solanki S, Kulkarni AP, Gutierrez LAR, Bader A, Brasseur A, Baptista N, Lheureux O, Vincent JL, Creteur J, Taccone FS, Hempel D, Stauffert N, Recker F, Schröder T, Reusch S, Schleifer J, Escoval A, Breitkreutz R, Sjövall F, Perner A, Møller MH, Moraes RB, Borges FK, Guillen JAV, Zabaletta WJC, Ruiz-Ramos J, Ramirez P, Tomas E, Marqués-Miñana MR, Villarreal E, Gordon M, Sosa M, Concha P, Castellanos A, Menendez R, Ramírez CS, Santana MC, Balcázar LC, Agrawal R, Escalada SH, Viera MAH, Vázquez CFL, Díaz JJD, Campelo FA, Monroy NS, Santana PS, Santana SR, Gutiérrez-Pizarraya A, Garnacho-Montero J, Mathew R, Martin C, Baumstarck K, Leone M, Martín-Loeches I, Pirracchio R, Legrand M, Mainardi JL, Mantz J, Cholley B, Hubbard A, Varma A, Frontera PR, Vega LMC, Miguelena PRDG, Usón MCV, López AR, Clemente EA, Ibañes PG, Aguilar ALR, Palomar M, Olaechea P, Dima E, Uriona S, Vallverdu M, Catalan M, Nuvials X, Aragon C, Lerma FA, Jeon YD, Jeong WY, Kim MH, Jeong IY, Charitidou E, Ahn MY, Ahn JY, Han SH, Choi JY, Song YG, Kim JM, Ku NS, Bassi GL, Xiol EA, Senussi T, Perivolioti E, Idone FA, Motos A, Chiurazzi C, Travierso C, Fernández-Barat L, Amaro R, Hua Y, Ranzani OT, Bobi Q, Rigol M, Pratikaki M, Torres A, Fernández IF, Soler EA, de Vera APR, Pastor EE, Hernandis V, Ros Martínez J, Rubio RJ, Torner MM, Brugger SC, Vrettou C, Eroles AA, Moles SI, Cabello JT, Schoenenberger JA, Casals XN, Vidal MV, Garrido BB, Martinez MP, Mirabella L, Cotoia A, Giannopoulos A, Tullo L, Stella A, Di Bello F, Di Gregorio A, Dambrosio M, Cinnella G, Rosario LEDLC, Lesmes SPG, Romero JCG, Herrera ANG, Zakynthinos S, Pertuz EDD, Sánchez MJG, Sanz ER, Hualde JB, Hernández AA, Ramirez JR, Takahashi H, Kazutoshi F, Okada Y, Oobayashi W, Routsi C, Naito T, Baidya DK, Maitra S, Anand RK, Ray BR, Arora MK, Ruffini C, Rota L, Corona A, Sesana G, Atchade E, Ravasi S, Catena E, Naumann DN, Mellis C, Husheer SL, Bishop J, Midwinter MJ, Hutchings S, Corradi F, Brusasco C, Houzé S, Manca T, Ramelli A, Lattuada M, Nicolini F, Gherli T, Vezzani A, Young A, Carmona AF, Santiago AI, Guillamon LN, Jean-Baptiste S, Delgado MJG, Delgado-Amaya M, Curiel-Balsera E, Rivera-Romero L, Castillo-Lorente E, Carrero-Gómez F, Aguayo-DeHoyos E, Healey AJ, Cameron C, Jiao L, Thabut G, Stümpfle R, Pérez A, Martin S, del Moral OL, Toval S, Rico J, Aldecoa C, Oguzhan K, Demirkiran O, Kirman M, Genève C, Bozbay S, Kosuk ME, Asyralyyeva G, Dilek M, Duzgun M, Telli S, Aydin M, Yilmazer F, Hodgson LE, Dimitrov BD, Tanaka S, Stubbs C, Forni LG, Venn R, Vedage D, Shawaf S, Naran P, Sirisena N, Kinnear J, Dimitrov BD, Hodgson LE, Lortat-Jacob B, Stubbs C, Forni LG, Venn R, Londoño JG, Cardenas CL, Ginés AS, Gubianas CM, Sánchez EC, Sirvent JM, Panafidina V, Augustin P, Shlyk I, Ilyina V, Judickas S, Kezyte G, Urbanaviciute I, Serpytis M, Gaizauskas E, Sipylaite J, Sprung CL, Munteanu G, Desmard M, Morales RC, Kasdan H, Volker T, Reiter A, Cohen Y, Himmel Y, Meissonnier J, Banderas-Bravo ME, Gómez-Jiménez C, García-Martínez MV, Montravers P, Martínez-Carmona JF, Fernández-Ortega JF, O‘Dwyer MJ, Starczewska M, Wilks M, Vincent JL, Torsvik M, Gustad LT, Bangstad IL, Vinje LJ, de Molina FJG, Damås JK, Solligård E, Mehl A, Tsunoda M, Kang M, Saito M, Saito N, Akizuki N, Namiki M, Takeda M, Barbadillo S, Yuzawa J, Yaguchi A, Frantzeskaki F, Tsirigotis P, Chondropoulos S, Paramythiotou E, Theodorakopoulou M, Stamouli M, Gkirkas K, Dimopoulou IK, Alejandro R, Makiko S, Tsunoda M, Kang M, Yuzawa J, Akiduki N, Namiki M, Takeda M, Yaguchi A, Preau S, Ambler M, Álvarez-Lerma F, Sigurta A, Saeed S, Singer M, Jochmans S, Chelly J, Vong LVP, Sy O, Serbource-Goguel J, Rolin N, Weyer CM, Vallés J, Abdallah RI, Adrie C, Vinsonneau C, Monchi M, Mayr U, Huber W, Karsten E, Lahmer T, Thies P, Henschel B, Catalán RM, Fischer G, Schmid RM, Ediboglu O, Ataman S, Naz I, Yaman G, Kirakli C, Su PL, Kou PS, Lin WC, Palencia E, Chen CW, Lozano JAB, Sánchez PC, Francioni JEB, Ferrón FR, Simón JMS, Riad Z, Mezidi M, Aublanc M, Perinel S, Jareño A, Lissonde F, Louf-Durier A, Yonis H, Tapponnier R, Richard JC, Louis B, Guérin C, Mezidi M, Yonis H, Aublanc M, Granada RM, Lissonde F, Louf-Durier A, Perinel S, Tapponnier R, Richard JC, Guérin C, Marmanidou K, Oikonomou M, Nouris C, Loizou C, Ignacio ML, Soilemezi E, Matamis D, Somhorst P, Gommers D, Hayashi K, Hirayama T, Yumoto T, Tsukahara K, Iida A, Nosaka N, Cui N, Sato K, Ugawa T, Nakao A, Ujike Y, Hirohata S, Mojoli F, Torriglia F, Giannantonio M, Orlando A, Bianzina S, Liu D, Tavazzi G, Mongodi S, Pozzi M, Iotti GA, Braschi A, Jansen D, Gadgil S, Doorduin J, Roesthuis L, van der Hoeven JG, Wang H, Heunks LMA, Chen GQ, Sun XM, He X, Yang YL, Shi ZH, Xu M, Zhou JX, Pereira SM, Tucci MR, Su L, Tonelotto BFF, Simoes CM, Morais CCA, Pompeo MS, Kay FU, Amato MBP, Vieira JE, Suzuki S, Mihara Y, Hikasa Y, Qiu H, Okahara S, Morimatsu H, Kwon HM, Moon YJ, Lee SH, Jung KW, Shin WJ, Jun IG, Song JG, Hwang GS, Li R, Lee S, Moon YJ, Kwon HM, Jung K, Shin WJ, Jun IG, Song JG, Hwang GS, Ramelli A, Manca T, Jaffal K, Corradi F, Brusasco C, Nicolini F, Gherli T, Brianti R, Fanzaghi P, Vezzani A, Tudor BA, Klaus DA, Lebherz-Eichinger D, Rouzé A, Lechner C, Schwarz C, Bodingbauer M, Seemann R, Kaczirek K, Fleischmann E, Roth GA, Krenn CG, Malyshev A, Sergey S, Poissy J, Yamaguchi Y, Nomura T, Yoshitake E, Idei M, Yoshida T, Takaki S, Yamaguchi O, Kaneko M, Goto T, Tencé N, Sendid B, Zaien I, Wolf M, Trouiller P, Jacobs FM, Kelly JM, Veigas P, Hollands S, Min A, Rizoli S, Robles CMC, Nseir S, de Oca Sandoval MAM, Tarabrin O, Gavrychenko D, Mazurenko G, Tarabrin P, Garcia IP, Martin AD, Mendez MC, orden VA, Noval RL, Paramythiotou E, McCue C, Gemmell L, MacKay A, Luján J, Villa P, Llorente B, Molina R, Alcázar L, Juanas CA, Rogero S, Rizos M, Pascual T, Cambronero JA, Almudévar PM, Domínguez JP, Carmona SA, Castañeda DP, Abellán AN, Lucendo AP, Pérez LP, Rivas RF, Frantzeskaki F, Sanz NM, Ramos JV, Villamizar PR, Javadpour S, Kalani N, Amininejad T, Jamali S, Sobhanian S, Laurent A, Bonnet M, Antoniadou A, Rigal R, Aslanian P, Hebert P, Capellier G, Contreras MRD, Mejías CR, Ruiz FCS, Lombardo MD, Perez JC, de Hoyos EA, Vourli S, Estella A, Viciana R, Fontaiña LP, Rico T, Madueño VP, Recuerda M, Fernández L, Sandiumenge A, Bonet S, Mazo C, Zerva L, Rubiera M, Ruiz-Rodríguez JC, Gracia RM, Espinel E, Pont T, Kotsopoulos A, Jansen N, Abdo WF, Gopcevic A, Gavranovic Z, Armaganidis A, Vucic M, Glogoski MZ, Penavic LV, Horvat A, Martin-Villen L, Egea-Guerero JJ, Revuelto-Rey J, Aldabo-Pallas T, Correa-Chamorro E, Gallego-Corpa AI, Riera J, Granados PRDPR, Faivre V, Wildenberg L, Huot B, Lukaszewicz AC, Simsir M, Mengelle C, Payen D, Sanz NM, Valbuena BL, Gottlieb J, de la Fuente MV, Almudena PM, Pérez LP, Carmona SA, Abellán AN, Simón IF, Muñoz JJR, Ramos JV, Carmona SA, Almudevar PM, Greer M, Abellan AN, Lucendo MAP, Perez LP, Dominguez JP, Rivas RF, Villamizar PR, Wee S, Ong C, Lau YH, Wong Y, Wiesner O, Banderas-Bravo ME, Olea-Jiménez V, Mora-Ordóñez JM, Gómez-Jiménez C, Muñoz-Muñoz JL, Vallejo-Báez J, Daga-Ruiz D, Lebrón-Gallardo M, Rialp G, Raurich JM, Martínez M, Morán I, Martín MC, Heras G, Mas A, Vallverdú I, Hraiech S, Bourenne J, Guervilly C, Forel JM, Adda M, Acuña M, Sylla P, Mouaci A, Gainnier M, Papazian L, Bauer PR, Kumbamu A, Wilson ME, Pannu JK, Egginton JS, Kashyap R, Rello J, Gajic O, Yoshihiro S, Sakuraya M, Hayakawa M, Hirata A, Kawamura N, Tsutui T, Yoshida K, Hashimoto Y, Chang CH, Welte T, Hu HC, Chiu LC, Hung CY, Li SH, Kao KC, Sibley S, Drover J, D’Arsigny C, Parker C, Howes D, Atchade E, Moffatt S, Erb J, Ilan R, Messenger D, Ball I, Boyd JG, Harrison M, Ridi S, Muscedere J, Andrade AH, Mignot T, Costa RC, Souza VA, Gonzalez V, Amorim V, Rolla F, Filho CACA, Miranda R, Atchasiri S, Buranavanich P, Wathanawatthu T, Houzé S, Suwanpasu S, Bureau C, Rolland-Debord C, Poitou T, Clavel M, Perbet S, Terzi N, Kouatchet A, Similowski T, Demoule A, Jean-Baptiste S, Diaz P, Nunes J, Escórcio S, Silva G, Chaves S, Jardim M, Câmara M, Fernandes N, Duarte R, Jardim JJ, Thabut G, Pereira CA, Nóbrega JJ, Chen CM, Lai CC, Cheng KC, Chou W, Lee SJ, Cha YS, Lee WY, Onodera M, Lortat-Jacob B, Nakataki E, Oto J, Imanaka H, Nishimura M, Khadjibaev A, Sabirov D, Rosstalnaya A, Akalaev R, Parpibaev F, Antonucci E, Tanaka S, Rossini P, Gandolfi S, Montini E, Orlando S, van Nes M, Karachi F, Hanekom S, Andrade AH, Pereira UV, Filho CACA, Augustin P, Costa RC, Parkin MSW, Moore M, Andrade AH, Costa RC, Carvalho KVS, Filho CACA, Min HJ, Kim HJ, Lee DS, Desmard M, Choi YY, Lee EY, Song I, Kim DJ, E YY, Kim JW, Park JS, Cho YJ, Lee JH, Suh JW, Montravers P, Jo YH, Kim KS, Lee YJ, Ferrero-Calleja J, Merino-Vega D, González-Jiménez AI, Sigcha MS, Hernández-Tejedor A, Martin-Vivas A, Gabán-Díez Á, Soussi S, Luna RRD, De la Calle-Pedrosa N, Temprano-Gómez I, Afonso-Rivero D, Pellin-Ariño JI, Algora-Weber A, Fumis RRL, Ferraz AB, Junior JMV, Kirca H, Dudoignon E, Cakin O, Unal M, Mutlu H, Ramazanoglu A, Cengiz M, Nicolini EA, Pelisson FGF, Nunes RS, da Silva SL, Carreira MM, Ferry A, Bellissimo-Rodrigues F, Ferez MA, Basile-Filho A, Chao HC, Chen CM, Chen L, Hravnak M, Clermont G, Pinsky M, Dubrawski A, Chaussard M, Varas JL, Montero RM, Sánchez-Elvira LA, Díaz PV, Delgado CP, Ruiz BL, Guerrero AP, Galache JAC, Sherif H, Hassanin H, Benyamina M, El Hossainy R, Samy W, Ly H, David H, Burtin P, Charpentier C, Barral M, Courant P, Fournel E, Gaide-Chevronnay L, Alanio A, Durand M, Albaladejo P, Payen JF, Chavanon O, Ortiz AB, Pozzebon S, Lheureux O, Brasseur A, Vincent JL, Creteur J, Touratier S, Taccone FS, Fumagalli F, Scala S, Affatato R, De Maglie M, Zani D, Novelli D, Marra C, Luciani A, De Zani D, Chaouat M, Luini M, Letizia T, Pravettoni D, Staszewsky L, Masson S, Belloli A, Di Giancamillo M, Scanziani E, Latini R, Ristagno G, Lafaurie M, Kye YC, Suh GJ, Kwon WY, Kim KS, Yu KM, Babini G, Ristagno G, Grassi L, Fumagalli F, Bendel S, Mimoun M, De Maglie M, Affatato R, Masson S, Latini R, Scanziani E, Reinikainen M, Skrifvars M, Kappler F, Blobner M, Schaller SJ, Mebazaa A, Roasio A, Costanzo E, Cardellino S, Iesu E, Cavicchi FZ, Fontana V, Nobile L, Vincent JL, Creteur J, Taccone FS, Legrand M, Park M, You KM, Suh GJ, Kwon WY, Ko SB, Kim KS, Xini A, Marca L, Lheureux O, Brasseur A, Sheils MA, Vincent JL, Creteur J, Taccone FS, Beane A, Thilakasiri MCKT, De Silva AP, Stephens T, Sigera CS, Athapattu P, Jayasinghe S, Patel C, Padeniya A, Haniffa R, Santiago AI, Sáez VC, Ruiz-Ruano RDLC, González AS, Kunze-Szikszay N, Wand S, Klapsing P, Wetz A, Mohankumar L, Heyne T, Schwerdtfeger K, Troeltzsch M, Bauer M, Quintel M, Moerer O, Cook DJ, Rutherford WB, Scales DC, Adhikari NK, Akhtar N, Cuthbertson BH, Suzuki T, Takei T, Fushimi K, Iwamoto M, Nakagawa S, Mendsaikhan N, Begzjav T, Lundeg G, Dünser MW, Noriega SKP, Romero DG, Cabrera JLS, Santana JDM, Padilla YS, Pérez HR, Torrent RL, Kleinpell R, Chouris I, Radu V, Stougianni M, Aldana NN, Lavrentieva A, Lagonidis D, Price RDT, Day A, Arora N, Henderson MA, Hickey S, Costa MIA, Carvalho JP, Gomes AA, León JLÁ, Mergulhão PJ, Chan KKC, Shum HP, Yan WW, Maghsoudi B, Tabei SH, Masjedi M, Sabetian G, Tabatabaei HR, Akbarzadeh A, Baquero JD, Saigal S, Pakhare A, Joshi R, Pattnaik SK, Ray B, Rousseau AF, Michel L, Bawin M, Cavalier E, Reginster JY, Bernal FF, Damas P, Bruyere O, Zhou JC, Cauwenberghs H, De Backer A, Neels H, Deblier I, Berghmans J, Himpe D, Barea-Mendoza JA, Ahmadnia E, Portillo IP, Fernández MV, Gigorro RG, Vela JLP, Mateos HM, Alves SC, Varas GM, Rodriguez-Biendicho A, Carreño ER, González JCM, Hadley JS, Yang JS, Chiang CH, Hung WT, Huang WC, Cheng CC, Lin KC, Lin SC, Chiou KR, Wann SR, Lin KL, Millar M, Kang PL, Mar GY, Liu CP, Zhou JC, Choi YJ, Yoon SZ, Gordillo-Brenes A, Fernandez-Zamora MD, Perez-Borrero L, Arias-Verdu MD, Hall D, Aguilar-Alonso E, Herruzo-Aviles A, Garcia-Delgado M, Hinojosa-Perez R, Curiel-Balsera E, Rivera-Fernandez R, Lesmes SPG, Rosario LEDLC, Hernández AA, Herrera ANG, Hewitt H, Sanz ER, Sánchez MJG, Hualde JB, Pascual OA, León JPT, Irazabal JMG, Pérez AG, Fernández PA, Amor LL, Albaiceta GM, Yasuda H, Lesmes SPG, Rosario LEDLC, Hernández AA, Sanz ER, Sánchez MJG, Calvo SA, Herrera ANG, Hualde JB, Pascual OA, León JPT, Sanui M, Corona A, Ruffini C, Spazzadeschi A, Marrazzo F, Gandola A, Sciurti R, Savi C, Catena E, Ke MW, Cheng CC, Komuro T, Huang WC, Chiang CH, Hung WT, Lin KC, Lin SC, Wann SR, Chiou KR, Tseng CJ, Kang PL, Mar GY, Kawano S, Liu CP, Bertini P, De Sanctis F, Guarracino F, Bertini P, Baldassarri R, Guarracino F, Buitinck SH, van der Voort PHJ, Oto J, Andoh K, Nakataki E, Tsunano Y, Izawa M, Tane N, Onodera M, Nishimura M, Ghosh S, Gupta A, De Gasperi A, Mazza E, Yamamoto H, Limuti R, Prosperi M, Bissenova N, Yergaliyeva A, Talan L, Yılmaz G, Güven G, Yoruk F, Altıntas ND, Mukherjee DN, Noda E, Agarwal LK, Mandal K, Palomar M, Balsera B, Vallverdu M, Martinez M, Garcia M, Castellana D, Lopez R, Barcenilla F, Hatakeyama J, Kaminsky GE, Carreño R, Escribá A, Fuentes M, Gálvez V, Del Olmo R, Nieto B, Vaquerizo C, Alvarez J, De la Torre MA, Saitou N, Torres E, Bogossian E, Nouer SA, Salgado DR, Brugger SC, Jiménez GJ, Torner MM, Vidal MV, Garrido BB, Casals XN, Okamoto H, Gaite FB, Cabello JT, Martínez MP, Doganci M, Izdes S, Besevli SG, Alkan A, Kayaaslan B, Ramírez CS, Balcázar LC, Kobayashi A, Santana MC, Viera MAH, Escalada SH, Vázquez CFL, Penichet SMM, Campelo FA, López MADLC, Santana PS, Santana SR, Repessé X, Takei T, Artiguenave M, Paktoris-Papine S, Espinasse F, Dinh A, El Sayed F, Charron C, Géri G, Vieillard-Baron A, Marmanidou K, Oikonomou M, Matsukubo S, Nouris C, Dimitroulakis K, Soilemezi E, Matamis D, Ferré A, Guillot M, Teboul JL, Lichtenstein D, Mézière G, Richard C, Rotzel HB, Monnet X, Pham T, Beduneau G, Schortgen F, Piquilloud L, Zogheib E, Jonas M, Grelon F, Runge I, Terzi N, Lázaro AS, Grangé S, Barberet G, Guitard PG, Frat JP, Constan A, Chrétien JM, Mancebo J, Mercat A, Richard JCM, Brochard L, Prada DA, Prīdāne S, Sabeļņikovs O, Mojoli F, Orlando A, Bianchi I, Torriglia F, Bianzina S, Pozzi M, Iotti GA, Braschi A, Gimillo MR, Beduneau G, Pham T, Schortgen F, Piquilloud L, Zogheib E, Jonas M, Grelon F, Runge I, Terzi N, Grangé S, Barinas OD, Barberet G, Guitard PG, Frat JP, Constan A, Chrétien JM, Mancebo J, Mercat A, Richard JCM, Brochard L, Kondili E, Cortes MLB, Psarologakis C, Kokkini S, Amargianitakis V, Babalis D, Chytas A, Chouvarda I, Vaporidi K, Georgopoulos D, Trapp O, Kalenka A, Franco JF, Mojoli F, Orlando A, Bianchi I, Torriglia F, Bianzina S, Pozzi M, Iotti GA, Braschi A, Lozano JAB, Sánchez PC, Roca JMS, Francioni JEB, Ferrón FR, Simón JMS, Spadaro S, Karbing DS, Gioia A, Moro F, Corte FD, Mauri T, Volta CA, Carratalá A, Rees SE, Petrova MV, Mohan R, Butrov AV, Beeharry SD, Vatsik MV, Sakieva FI, Gobert F, Yonis H, Tapponnier R, Gonçalves B, Fernandez R, Labaune MA, Burle JF, Barbier J, Vincent B, Cleyet M, Richard JC, Guérin C, Shinotsuka CR, Creteur J, Turon R, Taccone FS, Törnblom S, Nisula S, Vaara S, Poukkanen M, Andersson S, Pettilä V, Pesonen E, Xie Z, Liao X, Mendes A, Kang Y, Zhang J, Kubota K, Egi M, Mizobuchi S, Hegazy S, El-Keraie A, El Sayed E, El Hamid MA, Rodrigues NJ, Miranda F, Pereira M, Godinho I, Gameiro J, Neves M, Gouveia J, e Silva ZC, Lopes JA, Mckinlay J, Kostalas M, Kooner G, Mata PJ, Dudas G, Horton A, Kerr C, Karanjia N, Creagh-Brown B, Forni L, Yamazaki A, Ganuza MS, Molina JAM, Martinez FH, Cavalcanti D, Freile MTC, Fernandez NG, Travieso PM, Bandert A, Frithiof R, Lipcsey M, Smekal D, Schlaepfer P, Durovray JD, Plouhinec V, Melo N, Chiappa C, Bellomo R, Schneider AG, Mitchell S, Durrant J, Street H, Dunthorne E, Shears J, Caballero CH, Hutchison R, Lacerda P, Schwarze S, Ghabina S, Thompson E, Prowle JR, Kirwan CJ, Gonzalez CA, Pinto JL, Orozco V, Patiño JA, Garcia PK, Kurtz P, Contreras KM, Rodriguez P, Echeverri JE, Righy C, Rosario LEDLC, Lesmes SPG, Romero JCG, Herrera ANG, Pertuz EDD, Sánchez MJG, Sanz ER, Hualde JB, Hernández AA, Irazabal JMG, Spatenkova V, Bradac O, Suchomel P, Urli T, Lazzeri EH, Aspide R, Zanello M, Perez-Borrero L, Garcia-Alvarez JM, Arias-Verdu MD, Aguilar-Alonso E, Rivera-Fernandez R, Mora-Ordoñez J, De La Fuente-Martos C, Castillo-Lorente E, Guerrero-Lopez F, Lesmes SPG, Rosario LEDLC, Pertuz EDD, Hernández AA, Romero JCG, Sánchez MJG, Herrera ANG, Ramírez JR, Sanz ER, Hualde JB, León JPT, Navarro-Guillamón L, Cordovilla-Guardia S, Iglesias-Santiago A, Guerrero-López F, Fernández-Mondéjar E, Vidal A, Perez M, Juez A, Arias N, Colino L, Perez JL, Pérez H, Calpe P, Alcala MA, Robaglia D, Perez C, Lan SK, Cunha MM, Moreira T, Santos F, Lafuente E, Fernandes MJ, Silva JG, Rosario LEDLC, Lesmes SPG, Herrera ANG, Romero JCG, Pertuz EDD, Sánchez MJG, Sanz ER, Echeverría JGA, Hernández AA, Hualde JB, Podlepich V, Sokolova E, Alexandrova E, Lapteva K, Kurtz P, Shuinotsuka C, Rabello L, Vianna G, Reis A, Cairus C, Salluh J, Bozza F, Torres JCB, Araujo NJF, García-Olivares P, Keough E, Dalorzo M, Tang LK, De Sousa I, Díaz M, Marcos-Zambrano LJ, Guerrero JE, Gomez SEZ, Lopez GDH, Cuellar AIV, Nieto ORP, Gonzalez JAC, Bhasin D, Rai S, Singh H, Gupta O, Bhattal MK, Sampley S, Sekhri K, Nandha R, Aliaga FA, Olivares F, Appiani F, Farias P, Alberto F, Hernández A, Pons S, Sonneville R, Bouadma L, Neuville M, Mariotte E, Radjou A, Lebut J, Chemam S, Voiriot G, Dilly MP, Mourvillier B, Dorent R, Nataf P, Wolff M, Timsit JF, Ediboglu O, Ataman S, Ozkarakas H, Kirakli C, Vakalos A, Avramidis V, Obukhova O, Kurmukov IA, Kashiya S, Golovnya E, Baikova VN, Ageeva T, Haritydi T, Kulaga EV, Rios-Toro JJ, Perez-Borrero L, Aguilar-Alonso E, Arias-Verdu MD, Garcia-Alvarez JM, Lopez-Caler C, De La Fuente-Martos C, Rodriguez-Fernandez S, Sanchez-Orézzoli MG, Martin-Gallardo F, Nikhilesh J, Joshi V, Villarreal E, Ruiz J, Gordon M, Quinza A, Gimenez J, Piñol M, Castellanos A, Ramirez P, Jeon YD, Jeong WY, Kim MH, Jeong IY, Ahn MY, Ahn JY, Han SH, Choi JY, Song YG, Kim JM, Ku NS, Shah H, Kellner F, Rezai F, Mistry N, Yodice P, Ovnanian V, Fless K, Handler E, Alejos RM, Romeu JDM, Antón DG, Quinart A, Martí AT, Llaurado-Serra M, Lobo-Civico A, Ventura-Rosado A, Piñol-Tena A, Pi-Guerrero M, Paños-Espinosa C, Peralvo-Bernat M, Marine-Vidal J, Gonzalez-Engroba R, Montesinos-Cerro N, Treso-Geira M, Valeiras-Valero A, Martinez-Reyes L, Sandiumenge A, Jimenez-Herrera MF, Helyar S, Riozzi P, Noon A, Hallows G, Cotton H, Keep J, Hopkins PA, Taggu A, Renuka S, Sampath S, Rood PJT, Frenzel T, Verhage R, Bonn M, Pickkers P, van der Hoeven JG, van den Boogaard M, Corradi F, Melnyk L, Moggia F, Pienovi R, Adriano G, Brusasco C, Mariotti L, Lattuada M, Bloomer MJ, Coombs M, Ranse K, Endacott R, Maertens B, Blot K, Blot S, Amerongen MPVN, van der Heiden ES, Twisk JWR, Girbes ARJ, Spijkstra JJ, Riozzi P, Helyar S, Cotton H, Hallows G, Noon A, Bell C, Peters K, Feehan A, Keep J, Hopkins PA, Churchill K, Hawkins K, Brook R, Paver N, Endacott R, Maistry N, van Wijk A, Rouw N, van Galen T, Evelein-Brugman S, Taggu A, Krishna B, Sampath S, Putzu A, Fang M, Berto MB, Belletti A, Cassina T, Cabrini L, Mistry M, Alhamdi Y, Welters I, Abrams ST, Toh CH, Han HS, Gil EM, Lee DS, Park CM, Winder-Rhodes S, Lotay R, Doyle J, Ke MW, Huang WC, Chiang CH, Hung WT, Cheng CC, Lin KC, Lin SC, Chiou KR, Wann SR, Shu CW, Kang PL, Mar GY, Liu CP, Dubó S, Aquevedo A, Jibaja M, Berrutti D, Labra C, Lagos R, García MF, Ramirez V, Tobar M, Picoita F, Peláez C, Carpio D, Alegría L, Hidalgo C, Godoy K, Bakker J, Hernández G, Sadamoto Y, Katabami K, Wada T, Ono Y, Maekawa K, Hayakawa M, Sawamura A, Gando S, Marin-Mateos H, Perez-Vela JL, Garcia-Gigorro R, Peiretti MAC, Lopez-Gude MJ, Chacon-Alves S, Renes-Carreño E, Montejo-González JC, Parlevliet KL, Touw HRW, Beerepoot M, Boer C, Elbers PWG, Tuinman PR, Abdelmonem SA, Helmy TA, El Sayed I, Ghazal S, Akhlagh SH, Masjedi M, Hozhabri K, Kamali E, Zýková I, Paldusová B, Sedlák P, Morman D, Youn AM, Ohta Y, Sakuma M, Bates D, Morimoto T, Su PL, Chang WY, Lin WC, Chen CW, Facchin F, Zarantonello F, Panciera G, De Cassai A, Venrdramin A, Ballin A, Tonetti T, Persona P, Ori C, Del Sorbo L, Rossi S, Vergani G, Cressoni M, Chiumello D, Chiurazzi C, Brioni M, Algieri I, Tonetti T, Guanziroli M, Colombo A, Tomic I, Colombo A, Crimella F, Carlesso E, Gasparovic V, Gattinoni L, Neto AS, Schmidt M, Pham T, Combes A, de Abreu MG, Pelosi P, Schultz MJ, Katira BH, Engelberts D, Giesinger RE, Ackerley C, Yoshida T, Zabini D, Otulakowski G, Post M, Kuebler WM, McNamara PJ, Kavanagh BP, Pirracchio R, Rigon MR, Carone M, Chevret S, Annane D, Eladawy S, El-Hamamsy M, Bazan N, Elgendy M, De Pascale G, Vallecoccia MS, Cutuli SL, Di Gravio V, Pennisi MA, Conti G, Antonelli M, Andreis DT, Khaliq W, Singer M, Hartmann J, Harm S, Carmona SA, Almudevar PM, Abellán AN, Ramos JV, Pérez LP, Valbuena BL, Sanz NM, Simón IF, Arrigo M, Feliot E, Deye N, Cariou A, Guidet B, Jaber S, Leone M, Resche-Rigon M, Baron AV, Legrand M, Gayat E, Mebazaa A, Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J, Herpain A, Su F, Post E, Taccone F, Vincent JL, Creteur J, Lee C, Hatib F, Jian Z, Buddi S, Cannesson M, Fileković S, Turel M, Knafelj R, Gorjup V, Stanić R, Gradišek P, Cerović O, Mirković T, Noč M, Tirkkonen J, Hellevuo H, Olkkola KT, Hoppu S, Lin KC, Hung WT, Chiang CC, Huang WC, Juan WC, Lin SC, Cheng CC, Lin PH, Fong KY, Hou DS, Kang PL, Wann SR, Chen YS, Mar GY, Liu CP, Paul M, Bougouin W, Geri G, Dumas F, Champigneulle B, Legriel S, Charpentier J, Mira JP, Sandroni C, Cariou A, Zimmerman J, Sullivan E, Noursadeghi M, Fox B, Sampson D, McHugh L, Yager T, Cermelli S, Seldon T, Bhide S, Brandon RA, Brandon RB, Zwaag J, Beunders R, Pickkers P, Kox M, Gul F, Arslantas MK, Genc D, Zibandah N, Topcu L, Akkoc T, Cinel I, Greco E, Lauretta MP, Andreis DT, Singer M, Garcia IP, Cordero M, Martin AD, Pallás TA, Montero JG, Rey JR, Malo LR, Montoya AAT, Martinez ADCA, Ayala LYD, Zepeda EM, Granillo JF, Sanchez JA, Alejo GC, Cabrera AR, Montenegro AP, Pham T, Beduneau G, Schortgen F, Piquilloud L, Zogheib E, Jonas M, Grelon F, Runge I, Terzi N, Grangé S, Barberet G, Guitard PG, Frat JP, Constan A, Chrétien JM, Mancebo J, Mercat A, Richard JCM, Brochard L, Soilemezi E, Koco E, Savvidou S, Nouris C, Matamis D, Di Mussi R, Spadaro S, Volta CA, Mariani M, Colaprico A, Antonio C, Bruno F, Grasso S, Rodriguez A, Martín-Loeches I, Díaz E, Masclans JR, Gordo F, Solé-Violán J, Bodí M, Avilés-Jurado FX, Trefler S, Magret M, Reyes LF, Marín-Corral J, Yebenes JC, Esteban A, Anzueto A, Aliberti S, Restrepo MI, Larsson JS, Redfors B, Ricksten SE, Haines R, Powell-Tuck J, Leonard H, Ostermann M, Berthelsen RE, Itenov TS, Perner A, Jensen JU, Ibsen M, Jensen AEK, Bestle MH, Bucknall T, Dixon J, Boa F, MacPhee I, Philips BJ, Doyle J, Saadat F, Samuels T, Huddart S, McCormick B, DeBrunnar R, Preece J, Swart M, Peden C, Richardson S, Forni L, Kalfon P, Baumstarck K, Estagnasie P, Geantot MA, Berric A, Simon G, Floccard B, Signouret T, Boucekine M, Fromentin M, Nyunga M, Sossou A, Venot M, Robert R, Follin A, Renault A, Garrouste M, Collange O, Levrat Q, Villard I, Thévenin D, Pottecher J, Patrigeon RG, Revel N, Vigne C, Mimoz O, Auquier P, Pawar S, Jacques T, Deshpande K, Pusapati R, Wood B, Pulham RA, Wray J, Brown K, Pierce C, Nadel S, Ramnarayan P, Azevedo JR, Montenegro WS, Rodrigues DP, Sousa SC, Araujo VF, Leitao AL, Prazeres PH, Mendonca AV, Paula MP, Das Neves A, Loudet CI, Busico M, Vazquez D, Villalba D, Lischinsky A, Veronesi M, Emmerich M, Descotte E, Juliarena A, Bisso MC, Grando M, Tapia A, Camargo M, Ulla DV, Corzo L, dos Santos HP, Ramos A, Doglia JA, Estenssoro E, Carbonara M, Magnoni S, Donald CLM, Shimony JS, Conte V, Triulzi F, Stretti F, Macrì M, Snyder AZ, Stocchetti N, Brody DL, Podlepich V, Shimanskiy V, Savin I, Lapteva K, Chumaev A, Tjepkema-Cloostermans MC, Hofmeijer J, Beishuizen A, Hom H, Blans MJ, van Putten MJAM, Longhi L, Frigeni B, Curinga M, Mingone D, Beretta S, Patruno A, Gandini L, Vargiolu A, Ferri F, Ceriani R, Rottoli MR, Lorini L, Citerio G, Pifferi S, Battistini M, Cordolcini V, Agarossi A, Di Rosso R, Ortolano F, Stocchetti N, Lourido CM, Cabrera JLS, Santana JDM, Alzola LM, del Rosario CG, Pérez HR, Torrent RL, Eslami S, Dalhuisen A, Fiks T, Schultz MJ, Hanna AA, Spronk PE, Wood M, Maslove D. ESICM LIVES 2016: part three. Intensive Care Med Exp 2016. [PMCID: PMC5042925 DOI: 10.1186/s40635-016-0100-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
31
|
Anadón C, Guil S, Simó-Riudalbas L, Moutinho C, Setien F, Martínez-Cardús A, Moran S, Villanueva A, Calaf M, Vidal A, Lazo PA, Zondervan I, Savola S, Kohno T, Yokota J, Ribas de Pouplana L, Esteller M. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 2016; 35:4422. [PMID: 27345394 PMCID: PMC4994013 DOI: 10.1038/onc.2016.27] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
32
|
Alliot C, Audouin N, Barbet J, Bonraisin A, Bossé V, Bourdeau C, Bourgeois M, Duchemin C, Guertin A, Haddad F, Huclier-Markai S, Kerdjoudj R, Laizé J, Métivier V, Michel N, Mokili M, Pageau M, Vidal A. Is there an interest to use deuteron beams to produce nonconventional radionuclides? Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)30100-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Vidal A, Rinaldo M, Brochard P, Baron J, Verdun-Esquer C. Grossesse et travail au CHU de Bordeaux : étude comparative de la fréquence des principales complications de la grossesse du personnel (hors personnel médical et de recherche) par rapport à la population générale. ARCH MAL PROF ENVIRO 2016. [DOI: 10.1016/j.admp.2015.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
34
|
Huerta-Leidenz N, Rodas-González A, Vidal A, Lopez-Nuñez J, Colina O. Carcass cut-out value and eating quality of longisssimus muscle from serially harvested savannah-raised Brahman-influenced cattle and water buffaloes in Venezuela. Anim Prod Sci 2016. [DOI: 10.1071/an14987] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Males (n = 132) of riverine water buffalo (Buffalo) and Brahman-influenced cattle (Brahman) were reared alike and serially harvested at four different ages (7, 17, 19 and 24 months) to compare cutting yield (%), eating quality and consumer acceptability of cube-roll steaks at 19 and 24 months of age (MOA), and to examine post-weaning castration effects. Brahman bulls outperformed Brahman steers and Buffalo male classes in the proportion of chuck-roll, medium-value and total valuable cuts (P < 0.05). At all harvest ages, Buffalo carcasses yielded higher (P < 0.05) percentages of trimmed fat, which resulted in a sustained decline of the proportion of total lean, edible cuts. Buffalo meat had a lower shear-force value and a higher proportion of tender steaks than did Brahman at 7 and 24 MOA (P < 0.05). Whereas trained panellists detected differences in sensorial attributes only at 7 months [when Buffalo steaks were rated as more tender and flavourful (P < 0.05) than Brahman steaks], consumer acceptability ratings for Buffalo meat trended to be higher when harvested at 19 and 24 MOA (P < 0.1). The increasing proportion of boneless lean cuts with age gives Brahman a clear, commercial advantage over Buffalo; however, Buffalo produces meat as juicy and flavourful as that of Brahman and exhibits superior eating quality if harvested at 7 or 24 MOA.
Collapse
|
35
|
Belena JM, Nunez M, Vidal A, Gasco C, Gilsanz C, Alcojor A, Anta D, Lopez AE. Use of second generation supra-glottic airway devices during laparoscopic cholecystectomy: a prospective, randomized comparison of LMA Proseal™, LMA SupremeTM and igel™. Acta Anaesthesiol Belg 2016; 67:121-128. [PMID: 29873467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
INTRODUCTION Supra-glottic airway devices (SADs) with an inbuilt drain channel, such as the LMA Proseal™ (LMA-P), LMA SupremeTM (LMA-S) and i-gel™ (i-gel), have been used for laparoscopic cholecystectomy. We compared safety, efficacy, and ease of use, as well as the incidence of adverse events between these devices. METHODS One hundred and eighty adult, ASA 1-3 patients scheduled to undergo elective cholecystectomy under general anesthesia were randomly allocated to one of three groups: LMA-P, LMA-S or i-gel. The primary outcome was to evaluate oropharyngeal leak pressure (OLP). Secondary outcomes were to evaluated speed of insertion, ease of insertion of the device and the drain tube, as well as the incidence of intraoperative adverse events and postoperative oropharyngeal discomfort (POPD). RESULTS Mean OLP was significantly higher for LMA-P (LMA-P 30.87; i-gel 29.28; LMA-S 29.02 cm H₂0, P = 0.007). OLP was correlated with a higher maximum tidal achieved volume (P = 0.025). Insertion times were shorter for the i-gel, which was 1.7 s faster to insert than LMA-P (P = 0.04). The success rate on first attempt was higher for the LMA-S (P = 0.004). The drain tube was easily inserted in the LMA-S group (p < 0.001). I-gel showed higher sore throat scoring 2 hours postoperatively (P = 0.008) and reported slower POPD decrease during that time (P < 0.001). CONCLUSIONS Among SAD's, LMA-S is the easiest to insert (including the drain tube), LMA-P achieved the best leak pressure, and i-gel fastest to insert, although associated with the worst POPD scoring.
Collapse
|
36
|
Anadón C, Guil S, Simó-Riudalbas L, Moutinho C, Setien F, Martínez-Cardús A, Moran S, Villanueva A, Calaf M, Vidal A, Lazo PA, Zondervan I, Savola S, Kohno T, Yokota J, Ribas de Pouplana L, Esteller M. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 2015; 35:4407-13. [PMID: 26640150 PMCID: PMC4842009 DOI: 10.1038/onc.2015.469] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 10/09/2015] [Accepted: 11/02/2015] [Indexed: 12/02/2022]
Abstract
The introduction of new therapies against particular genetic mutations in non-small-cell lung cancer is a promising avenue for improving patient survival, but the target population is small. There is a need to discover new potential actionable genetic lesions, to which end, non-conventional cancer pathways, such as RNA editing, are worth exploring. Herein we show that the adenosine-to-inosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mouse models, whereas its overexpression has the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early-stage lung cancer, but harboring ADAR1 gene amplification, have poor outcomes. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affects downstream RNA editing patterns and patient prognosis.
Collapse
Affiliation(s)
- C Anadón
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - S Guil
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - L Simó-Riudalbas
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - C Moutinho
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - F Setien
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - A Martínez-Cardús
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - S Moran
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - A Villanueva
- Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, Barcelona, Catalonia, Spain
| | - M Calaf
- Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, Barcelona, Catalonia, Spain
| | - A Vidal
- Department of Pathological Anatomy, Bellvitge Unviversity Hospital, Barcelona, Catalonia, Spain
| | - P A Lazo
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biologıa Molecular y Celular del Cancer, CSIC-Universidad de Salamanca, Salamanca, Spain.,Instituto de Investigacion Biomedica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
| | | | - S Savola
- MRC-Holland, Amsterdam, The Netherlands
| | - T Kohno
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
| | - J Yokota
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.,Genomics and Epigenomics of Cancer Prediction Program, Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Badalona, Catalonia, Spain
| | - L Ribas de Pouplana
- Institute for Research in Biomedicine (IRB), c/ Baldiri Reixac 10 08028, Barcelona, Catalonia, Spain.,Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain
| | - M Esteller
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.,Institute for Research in Biomedicine (IRB), c/ Baldiri Reixac 10 08028, Barcelona, Catalonia, Spain.,Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain
| |
Collapse
|
37
|
de la Cruz-Herrera CF, Baz-Martínez M, Lang V, El Motiam A, Barbazán J, Couceiro R, Abal M, Vidal A, Esteban M, Muñoz-Fontela C, Nieto A, Rodríguez MS, Collado M, Rivas C. Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation. Oncogene 2015; 35:2873-80. [DOI: 10.1038/onc.2015.356] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Revised: 07/17/2015] [Accepted: 08/22/2015] [Indexed: 12/19/2022]
|
38
|
Giráldez I, Ruiz-Azcona P, Vidal A, Morales E. Speciation of selenite and selenoamino acids in biota samples by dual stir bar sorptive extraction-single desorption-capillary gas chromatography/mass spectrometry. Microchem J 2015. [DOI: 10.1016/j.microc.2015.05.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
39
|
Barneda-Zahonero B, Collazo O, Azagra A, Fernández-Duran I, Serra-Musach J, Islam ABMMK, Vega-García N, Malatesta R, Camós M, Gómez A, Román-González L, Vidal A, López-Bigas N, Villanueva A, Esteller M, Parra M. The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell Death Dis 2015; 6:e1635. [PMID: 25675295 PMCID: PMC4669785 DOI: 10.1038/cddis.2014.594] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 12/16/2014] [Accepted: 12/18/2014] [Indexed: 12/26/2022]
Abstract
The generation of B cells is a complex process requiring several cellular transitions, including cell commitment and differentiation. Proper transcriptional control to establish the genetic programs characteristic of each cellular stage is essential for the correct development of B lymphocytes. Deregulation of these particular transcriptional programs may result in a block in B-cell maturation, contributing to the development of hematological malignancies such as leukemia and lymphoma. However, very little is currently known about the role of transcriptional repressors in normal and aberrant B lymphopoiesis. Here we report that histone deacetylase 7 (HDAC7) is underexpressed in pro-B acute lymphoblastic leukemia (pro-B-ALL) and Burkitt lymphoma. Ectopic expression of HDAC7 induces apoptosis, leads to the downregulation of c-Myc and inhibits the oncogenic potential of cells in vivo, in a xenograft model. Most significantly, we have observed low levels of HDAC7 expression in B-ALL patient samples, which is correlated with the increased levels of c-Myc. From a mechanistic angle, we show that ectopically expressed HDAC7 localizes to the nucleus and interacts with the transcription factor myocyte enhancer factor C (MEF2C) and the corepressors HDAC3 and SMRT. Accordingly, both the HDAC7–MEF2C interaction domain as well as its catalytic domain are involved in the reduced cell viability induced by HDAC7. We conclude that HDAC7 has a potent anti-oncogenic effect on specific B-cell malignancies, indicating that its deregulation may contribute to the pathogenesis of the disease.
Collapse
Affiliation(s)
- B Barneda-Zahonero
- Cellular Differentiation Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| | - O Collazo
- Cellular Differentiation Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| | - A Azagra
- Cellular Differentiation Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| | - I Fernández-Duran
- Cellular Differentiation Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| | - J Serra-Musach
- Breast Cancer and Systems Biology Unit, Translational Research Laboratory, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Avenida Gran Via s/n km 2.7, 08907 L'Hospitalet, Barcelona, Spain
| | - A B M M K Islam
- Department of Genetic Engineering & Biotechnology, University of Dhaka, Dhaka, Bangladesh
| | - N Vega-García
- Department of Hematology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - R Malatesta
- Department of Hematology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - M Camós
- Department of Hematology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - A Gómez
- Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| | - L Román-González
- Cellular Differentiation Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| | - A Vidal
- Department of Pathology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - N López-Bigas
- 1] Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr Aiguader 88, 08003 Barcelona, Spain [2] Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - A Villanueva
- Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain
| | - M Esteller
- 1] Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain [2] Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain [3] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain
| | - M Parra
- Cellular Differentiation Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research institute (IDIBELL), Avenida Gran Via 199, 08908 L'Hospitalet, Barcelona, Spain
| |
Collapse
|
40
|
Rodas-González A, Huerta-Leidenz N, Vidal A, Colina O, Lopez J, Rodriguez R. Comparison of water buffalo (Bubalus bubalis) with crossbred and purebred Brahman cattle for growth performance on savannah and slaughter traits at four ages in Venezuela. Anim Prod Sci 2015. [DOI: 10.1071/an13352] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Males (n = 132) of water buffalo (Buffalo), Brahman crossbred and purebred cattle (Brahman) were born, raised, weaned, castrated (half of the animals at 7 months) and fattened on the same grazing savannahs, and then slaughtered at four different ages (7, 17, 19 and 24 months) to compare growth and slaughter traits and examine post-weaning castration effects. Buffalo showed consistently faster weight gains and heavier carcasses but had lower dressing percentages than Brahman cattle due to higher proportions of hide, head, and red and white viscera at each age (P < 0.05). Additionally, Buffalo had abundant fat cover distribution, and whiter subcutaneous fat than Brahman (P < 0.05), this resulted in a higher proportion of Buffalo carcasses that graded in the second quality Venezuelan grade ‘A’ (P < 0.05). Regardless of species, bulls had higher average daily gain and liveweight than steers (P < 0.05); however, no differences were detected in carcass weight and dressing percentages (P > 0.05). Also, at the same weight steers produced carcasses with thicker back fat, more abundant fat cover distribution and whiter fat than bulls (P < 0.05). With respect to age groups, there were concomitant increases in slaughter weight, carcass weight, and dressing percentage as age increased (P < 0.01). As age advanced, carcasses had a more convex leg profile, abundant fat cover, thicker back fat, higher marbling and greater REA (P < 0.05). Based on the observed growth and carcass traits, Buffalo offer a promising alternative for meat production under savannah feeding production systems.
Collapse
|
41
|
Perrot Y, Degoul F, Auzeloux P, Bonnet M, Cachin F, Chezal JM, Donnarieix D, Labarre P, Moins N, Papon J, Rbah-Vidal L, Vidal A, Miot-Noirault E, Maigne L. Internal dosimetry through GATE simulations of preclinical radiotherapy using a melanin-targeting ligand. Phys Med Biol 2014; 59:2183-98. [PMID: 24710744 DOI: 10.1088/0031-9155/59/9/2183] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
de la Cruz-Herrera CF, Campagna M, Lang V, del Carmen González-Santamaría J, Marcos-Villar L, Rodríguez MS, Vidal A, Collado M, Rivas C. SUMOylation regulates AKT1 activity. Oncogene 2014; 34:1442-50. [PMID: 24704831 DOI: 10.1038/onc.2014.48] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Revised: 11/27/2013] [Accepted: 01/06/2014] [Indexed: 01/09/2023]
Abstract
Serine threonine kinase AKT has a central role in the cell, controlling survival, proliferation, metabolism and angiogenesis. Deregulation of its activity underlies a wide range of pathological situations, including cancer. Here we show that AKT is post-translationally modified by the small ubiquitin-like modifier (SUMO) protein. Interestingly, neither SUMO conjugation nor activation of SUMOylated AKT is regulated by the classical AKT targeting to the cell membrane or by the phosphoinositide 3-kinase pathway. We demonstrate that SUMO induces the activation of AKT, whereas, conversely, down-modulation of the SUMO machinery diminishes AKT activation and cell proliferation. Furthermore, an AKT SUMOylation mutant shows reduced activation, and decreased anti-apoptotic and pro-tumoral activities in comparison with the wild-type protein. These results identify SUMO as a novel key regulator of AKT phosphorylation and activity.
Collapse
Affiliation(s)
- C F de la Cruz-Herrera
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - M Campagna
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - V Lang
- Ubiquitylation and Cancer Molecular Biology laboratory, Inbiomed, San Sebastian-Donostia, Gipuzkoa, Spain
| | | | - L Marcos-Villar
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - M S Rodríguez
- Ubiquitylation and Cancer Molecular Biology laboratory, Inbiomed, San Sebastian-Donostia, Gipuzkoa, Spain
| | - A Vidal
- Departamento de Fisioloxía and Centro de Investigación en Medicina Molecular (CIMUS), Universidade de Santiago de Compostela, Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain
| | - M Collado
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
| | - C Rivas
- 1] Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain [2] Centro de Investigación en Medicina Molecular (CIMUS), Universidade de Santiago de Compostela, Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain
| |
Collapse
|
43
|
Vidal A, Viesti G, Pino F, Barros H, Sajo-Bohus L. Annihilation Radiation Gauge for Relative Density and Multiphase Fluid Monitoring. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146610017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Vidal A, Marín S, Morales H, Ramos AJ, Sanchis V. The fate of deoxynivalenol and ochratoxin A during the breadmaking process, effects of sourdough use and bran content. Food Chem Toxicol 2014; 68:53-60. [PMID: 24607819 DOI: 10.1016/j.fct.2014.03.006] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Revised: 02/10/2014] [Accepted: 03/02/2014] [Indexed: 11/29/2022]
Abstract
Deoxynivalenol (DON) and ochratoxin A (OTA) are mycotoxins produced by fungal species which can contaminate, alone or simultaneously, cereal-based products such as bread. Due to the increasing interest in the beneficial effects of dietary bran, bran bread has attained high consumption. Usually, the higher mycotoxin concentrations in cereals are found in the external layers of the grain (bran), leading to higher concentration of DON and OTA in breads with added bran. Moreover, the use of sourdough in breadmaking is increasing, but no studies about its effect in the mycotoxins content exist. The objective of this study was to determine the variation of concentration of these mycotoxins during the breadmaking process including the following factors: two initial mycotoxin concentrations in the initial mix of ingredients, four different bran contents, and use of sourdough. OTA was confirmed to be quite stable during the breadmaking process, regardless of the assayed factors. DON concentration during breadmaking was not significantly affected by bran content of bread. However, it was significantly affected by kneading and fermentation steps in opposite way depending on sourdough use and flour contamination level: if DON reduction occurs during fermentation, this leads to a safer situation, but the possible increase in DON should be considered with care, as it can compensate the expected dilution effect by recipe. Finally, the results on deoxynivalenol-3-glucoside (DON-3-G), although preliminar, suggest an increase of this toxin during fermentation, but mainly during baking.
Collapse
Affiliation(s)
- A Vidal
- Applied Mycology Unit, Food Technology Department, University of Lleida, UTPV-XaRTA, Agrotecnio Center, 25198 Lleida, Spain
| | - S Marín
- Applied Mycology Unit, Food Technology Department, University of Lleida, UTPV-XaRTA, Agrotecnio Center, 25198 Lleida, Spain.
| | - H Morales
- IBB - Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Braga, Portugal
| | - A J Ramos
- Applied Mycology Unit, Food Technology Department, University of Lleida, UTPV-XaRTA, Agrotecnio Center, 25198 Lleida, Spain
| | - V Sanchis
- Applied Mycology Unit, Food Technology Department, University of Lleida, UTPV-XaRTA, Agrotecnio Center, 25198 Lleida, Spain
| |
Collapse
|
45
|
Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res 2013; 20:658-67. [PMID: 24277456 DOI: 10.1158/1078-0432.ccr-13-1131] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE We examined whether PI3K-AKT or extracellular signal-regulated kinase (ERK) signaling pathways could play a role in the development of cisplatin (CDDP) resistance in testicular germ cell tumor (TGT) cells. EXPERIMENTAL DESIGN We compared AKT and ERK activation levels in CDDP-sensitive testicular tumor cells and in their corresponding CDDP-resistant-derived cells. We also analyzed these pathways in orthotopic testicular tumors and human patient samples. RESULTS Our results indicated that there was overactivation of AKT in CDDP-resistant cells compared with sensitive cells, but no effect on activated ERK levels. We observed an increase in mRNA and protein levels for platelet-derived growth factor (PDGF) receptor β and PDGF-B ligand. These were responsible for AKT overactivation in CDDP-resistant cells. When PDGFRβ levels were decreased by short hairpin RNA (shRNA) treatment or its activation was blocked by pazopanib, CDDP-resistant cells behaved like sensitive cells. Moreover, CDDP-resistant cells were more sensitive to incubation with PDGFRβ inhibitors such as pazopanib or sunitinib than sensitive cells, a finding consistent with these cells being dependent on this signaling pathway. We also found overexpression of PDGFRβ and pAKT in CDDP-resistant choriocarcinoma orthotopic tumor versus their CDDP-sensitive counterparts. Finally, we found high PDGFRβ levels in human testicular tumors, and overexpression in CDDP-resistant testicular choriocarcinomas compared with the CDDP-sensitive and nontreated tumors. CONCLUSIONS The PDGFRβ-AKT pathway plays a critical role in the development of CDDP resistance in testicular tumoral cells.
Collapse
Affiliation(s)
- M Juliachs
- Authors' Affiliations: Laboratori de Recerca Translacional and Servei d'Oncologia Mèdica, Institut Català d'Oncologia, Hospital Duran i Reynals; Servei d'Anatomia Patològica, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat; Departaments de Patologia i Terapèutica Experimental and Ciències Fisiològiques II, Universitat de Barcelona; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL); Laboratori d'Oncologia Molecular and Cancer Epigenetics and Biology Program (PEBC), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Garcia-Molla VM, Liberos A, Vidal A, Guillem MS, Millet J, Gonzalez A, Martinez-Zaldivar FJ, Climent AM. Adaptive step ODE algorithms for the 3D simulation of electric heart activity with graphics processing units. Comput Biol Med 2013; 44:15-26. [PMID: 24377685 DOI: 10.1016/j.compbiomed.2013.10.023] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2013] [Revised: 10/21/2013] [Accepted: 10/24/2013] [Indexed: 10/26/2022]
Abstract
In this paper we studied the implementation and performance of adaptive step methods for large systems of ordinary differential equations systems in graphics processing units, focusing on the simulation of three-dimensional electric cardiac activity. The Rush-Larsen method was applied in all the implemented solvers to improve efficiency. We compared the adaptive methods with the fixed step methods, and we found that the fixed step methods can be faster while the adaptive step methods are better in terms of accuracy and robustness.
Collapse
Affiliation(s)
- V M Garcia-Molla
- Department of Information Systems and Computing, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - A Liberos
- ITACA Institute, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - A Vidal
- Department of Information Systems and Computing, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - M S Guillem
- ITACA Institute, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - J Millet
- ITACA Institute, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - A Gonzalez
- ITEAM Institute, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - F J Martinez-Zaldivar
- ITEAM Institute, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| | - A M Climent
- ITACA Institute, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain.
| |
Collapse
|
47
|
Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. Int J Cancer 2013; 133:235-46. [PMID: 23292912 DOI: 10.1002/ijc.28009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 12/13/2012] [Indexed: 11/06/2022]
Abstract
In this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found high expression of ErbB3 in all GCTs tested. This pattern of expression was maintained when primary tumors were orthotopically implanted in nude mice. We have chosen a choriocarcinoma model characterized by high levels of ErbB1, but also of ErbB2 and ErbB3, to assay the in vivo effect of ErbB inhibitors on tumoral growth. Our results showed a complete lack of effect (refractoriness) to the pure ErbB1 receptor inhibitors cetuximab and gefitinib. While these inhibitors blocked ErbB1 phosphorylation, ErbB2 phosphorylation was not affected, suggesting an ErbB1-independent activation of this receptor. To confirm the importance of ErbB2 activation, animals were treated with lapatinib, a dual ErbB1 and ErbB2 inhibitor. Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3). ErbB2 activation could still occur due to the formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely inhibited by lapatinib. Finally, combined inhibition of ErbB1 (gefitinib) and ErbB3 activities (knockdown expression by shRNA) inhibited tumoral testicular cells proliferation in a similar way to lapatinib. Our results explain why lapatinib but not anti-ErbB1 agents might be effective for treatment of testicular GCT patients.
Collapse
Affiliation(s)
- M Juliachs
- Laboratori de Recerca Translacional, Institut Català d'Oncologia, Hospital Duran i Reynals, 08908 L'Hospitalet de Llobregat (Barcelona), Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Vidal A, Talens P, Prats-Montalbán JM, Cubero S, Albert F, Blasco J. In-Line Estimation of the Standard Colour Index of Citrus Fruits Using a Computer Vision System Developed For a Mobile Platform. FOOD BIOPROCESS TECH 2012. [DOI: 10.1007/s11947-012-1015-2] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Vidal A, Blanchemain JF, Verdun-Esquer C, Rinaldo M, Brochard P. Les effets respiratoires d’une exposition chronique et subaiguë à l’hydrogène sulfuré : rapport de cas de salariés de stations d’épuration des eaux usées. ARCH MAL PROF ENVIRO 2012. [DOI: 10.1016/j.admp.2012.07.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Valero MA, Vidal A, Burgos R, Calvo FL, Martínez C, Luengo LM, Cuerda C. [Meta-analysis on the role of lycopene in type 2 diabetes mellitus]. NUTR HOSP 2012; 26:1236-41. [PMID: 22411366 DOI: 10.1590/s0212-16112011000600007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2011] [Accepted: 07/19/2011] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION lycopene is a carotene with a potent antioxidant effect found in tomato and its derivatives. Given that diabetic patients present an increased oxidative stress, lycopene could be beneficial. The aim of this scientific review has been to analyze the scientific evidence of the role of lycopene as an anti-oxidant agent in diabetes, its prevention and the metabolic control and development of complications. MATERIALS AND METHODS We carried out a systematic review and meta-analysis. A literature search was done in Medline and the Cochrane Library, using the MeSH terms "carotenoids" OR "lycopene" AND "type 2 diabetes mellitus". The search was manually completed from the references of the papers found. The quality of the studies was assessed by using the JADAD and STROBE scales. We included a total of 10 articles. RESULTS After adjusting for other risk factors, the OR for developing DM2 as similar among the different levels of lycopene intake. The plasma levels of lycopene increase in the intervention groups. Lycopene decreases the malonyldialdehyde and lipid peroxidation. The non-provitamin A/provitamin A carotenoids ratio is negatively associated with the risk for suffering from diabetic retinopathy. CONCLUSION Tomato or lycopene intake increases the plasma levels of this compound. However, there is no evidence for the association between lycopene intake and the risk for having diabetes. This compound and other tomato derivatives may have a beneficial effect on the oxidative stress in diabetic patients. The non-provitamin A/provitamin A carotenoids ratio is negatively associated with the risk for suffering from diabetic retinopathy, although there are no data available on the relationship between lycopene and other diabetic complications.
Collapse
Affiliation(s)
- M A Valero
- Unidad de Nutrición, Hospital 12 de Octubre, Madrid, España.
| | | | | | | | | | | | | |
Collapse
|